- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
---------------
FORM 10-K
(Mark One)
[X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended September 30, 2000
OR
[_]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
Commission File Number 0-27410
---------------
INCARA PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 56-1924222
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
P.O. Box 14287
3200 East Highway 54
Cape Fear Building, Suite 300
Research Triangle Park, North Carolina
27709
(Address of principal executive offices)
Company's telephone number, including area code: 919-558-8688
Securities registered pursuant to Section 12(B) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.001 par value per share
---------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of the voting stock held by non-affiliates of the
registrant based upon the closing price of the Common Stock on December 4,
2000, on the Nasdaq National Market System was approximately $19,052,000 as of
such date. Shares of Common Stock held by each executive officer and director
and by each person who owns 10% or more of the outstanding Common Stock have
been excluded in that such persons might be deemed to be affiliates. This
determination of affiliate status might not be conclusive for other purposes.
As of December 4, 2000, the Registrant had outstanding 7,365,849 shares of
Common Stock.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Company's Proxy Statement for the 2001 Annual Meeting of
Stockholders are incorporated herein by reference into Part III.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
INCARA PHARMACEUTICALS CORPORATION
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
Page
----
PART I
Item 1. Business...................................................... 3
Item 2. Properties.................................................... 25
Item 3. Legal Proceedings............................................. 25
Item 4. Submission of Matters to a Vote of Security Holders........... 25
Executive Officers............................................ 26
PART II
Item 5. Market for Company's Common Equity and Related Stockholder
Matters....................................................... 27
Item 6. Selected Financial Data....................................... 27
Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations..................................... 29
Item 7A. Quantitative and Qualitative Disclosure of Market Risks....... 33
Item 8. Financial Statements and Supplementary Data................... 33
Item 9. Changes In and Disagreements With Accountants on Accounting
and Financial Disclosure...................................... 33
PART III
Item 10. Directors and Executive Officers of the Registrant............ 34
Item 11. Executive Compensation........................................ 34
Item 12. Security Ownership of Certain Beneficial Owners and
Management.................................................... 34
Item 13. Certain Relationships and Related Transactions................ 34
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form
8-K........................................................... 35
2
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Form 10-K contains forward-looking statements that relate to future
events or our future financial performance. You can identify forward-looking
statements by terminology such as "may," "might," "will," "could," "should,"
"would," "expect," "plan," "anticipate," "believe," "estimate," "predict,"
"intend," "potential" or "continue" or the negative of these terms or other
comparable terminology. Our actual results might differ materially from any
forward-looking statement due to various risks, uncertainties and
contingencies, including:
. The success or failure of our efforts to implement our business strategy;
. The early stage of the products we are developing;
. Uncertainties relating to clinical trials and regulatory reviews;
. The need for additional funds;
. Competition and dependence on collaborative partners;
. The other factors and risks described under the section captioned
"Business--Risks Associated with the Company's Business".
Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements.
Item 1. Business.
Overview
Incara Pharmaceuticals Corporation develops innovative pharmaceutical
products and treatments for major diseases afflicting large patient
populations. We are currently developing a diversified portfolio of three
potentially breakthrough treatments. Each of these products targets a medical
disorder for which there are no fully effective treatments. These three
products are as follows:
. OP2000, an ultra-low molecular weight heparin. Heparin is a naturally
occurring mixture of substances produced by the human body with anti-
clotting and anti-inflammatory properties. OP2000 is derived from heparin
by breaking it down into smaller molecules. Lower weight, or smaller,
molecules of heparin may prove to have certain advantages over heparin
itself, including better safety, efficacy and convenience. We are testing
OP2000 as a treatment for inflammatory bowel disease, or IBD. IBD is a
debilitating disease of the intestinal tract that includes ulcerative
colitis and Crohn's disease. Approximately two million patients suffer
from IBD in the United States and Europe combined. Ulcerative colitis can
be so debilitating that up to 20% of patients opt for removal of their
colon as a cure.
. Liver precursor cell transplant, as a treatment for liver failure. Liver
precursor cells are young cells found in the human liver that can grow
and divide many times. Our process purifies liver precursor cells from
the livers of organ donors with the expectation that these cells would be
transplanted into human patients with chronic liver disease. We believe
the cells will then be able to grow and expand to create new tissue in
the liver. Currently, there are an estimated 300,000 hospitalizations for
chronic liver disease each year in the United States, 30,000 of which
result in death. There are, however, only approximately 4,800 donor
livers available annually in the United States and over 16,500 people on
the liver transplant waiting list. The number of patients with such
severe cirrhosis that they could become candidates for a transplant
exceeds 100,000. Additionally, with the recent growth in interest in
human genomics, our liver precursor cell technology can assist in
determining which genes are active at the various stages in a liver
cell's maturation, providing valuable genomic information for drug
research.
. Small molecule catalytic antioxidants, as a treatment for stroke and
heart attack. Antioxidants destroy free radicals, which damage cells
within the human body and are thought to play a role in stroke, heart
attack and other illnesses. Catalytic antioxidants, unlike other
antioxidants, are not consumed by their
3
reaction with free radicals and, therefore, can destroy many free
radicals. An estimated 500,000 to 700,000 individuals suffer strokes in
the United States each year, with estimated direct costs of treating
stroke exceeding $40 billion annually. Our lead catalytic antioxidant
molecule significantly reduced damaged brain tissue when administered as
late as 7.5 hours after obstruction of blood flow in an animal model of
stroke.
These three programs reflect our business strategy of building a diversified
portfolio of innovative potential treatments by identifying research
discoveries from leading academic research centers. Incara applies human and
financial resources to these academic programs in order to focus efforts on
pharmaceutical development, including clinical trials. Our goal is to bring
these products to market. We choose products for our portfolio that have large
potential patient markets and can be studied in clinical trials for a
reasonable expenditure of time and money.
We generally plan to enter into relationships with companies that have
manufacturing, sales or marketing capabilities to bring our products to market.
We believe these relationships will provide funding for the commercialization
of our products and allow us to maintain our low fixed cost structure. We
generally intend to wait until we begin to receive indications that the
products work before entering into these relationships, which should allow us
to negotiate more favorable terms.
Our company was incorporated in Delaware as Intercardia, Inc. in 1994. In
July 1999 our company changed its name to Incara Pharmaceuticals Corporation.
OP2000
Our program for inflammatory bowel disease, or IBD, centers on OP2000, a
product derived from heparin. Heparin is a naturally occurring substance with
anti-clotting and anti-inflammatory properties. Heparin, as a pharmaceutical
product (including the starting material for OP2000), is derived and purified
from domestic mammals, primarily pigs. In July 1998 we obtained an exclusive
15-year license to develop OP2000 from its manufacturer, Opocrin S.p.A. of
Modena, Italy. Clinical evidence of the treatment of IBD with heparin and the
known anti-clotting effects of OP2000 and other heparin-derived products
provide the rationale for evaluating OP2000 in treating IBD. We have completed
two Phase 1 clinical trials in normal volunteers to determine blood levels and
anti-clotting effects following once daily injections of OP2000. Blood levels
are important in determining the dosage necessary for treatment. Assuming we
have adequate financial resources, we plan to begin a pivotal Phase 2/3
clinical trial in patients with ulcerative colitis by early 2001. For
information on the three sequential phases of clinical trials, see "Government
Regulation" below.
Inflammatory Bowel Disease
Inflammatory bowel disease describes a group of chronic inflammatory
disorders of the intestine of unknown cause, often causing recurrent abdominal
pain, cramps, diarrhea with or without bleeding, fever and fatigue. Two forms
of IBD are Crohn's disease and ulcerative colitis. Crohn's disease typically
affects the full thickness of the intestinal wall, most commonly in the lowest
portion of the small intestine, but may involve any portion of the
gastrointestinal tract. Ulcerative colitis results in the large intestine
becoming inflamed with open sores and bleeding. Current treatments of IBD, such
as steroids and other anti-inflammatory drugs, are designed to reduce
inflammation and relieve symptoms, but treatment results are often
unsatisfactory. In serious cases, surgery is required. Ulcerative colitis can
be so debilitating that up to 20% of patients opt for removal of their colon as
a cure. There is no cure for the equally debilitating Crohn's disease.
According to the Crohn's & Colitis Foundation of America, Inc.,
approximately one million people in the United States have IBD. We believe
there is a need for effective and safe treatments.
4
Heparins and IBD
A large number of case reports and a recent double blind placebo-controlled
clinical trial of heparin in ulcerative colitis support the idea that heparin
can safely induce remission in IBD patients. A review (Korzenik, IBD 1997) of
the clinical use of heparin in IBD (primarily ulcerative colitis) found benefit
in 51 out of 60 reported cases, with increased bleeding in only three cases. In
a recent U.S. double blind placebo-controlled trial of heparin in 68 patients
with active ulcerative colitis receiving treatment with standard therapies, 42%
of patients who were given additional heparin therapy had clinical remission or
improvement, compared with 20% on placebo.
Clinical observations suggest that IBD may result from increased clotting
activity. Investigators have observed evidence of increased clotting in the
bowel and other organs during flares of IBD. Clotting is activated and the
breakdown of clots is reduced during flares. Patients with inherited clotting
deficiencies, such as von Willebrand's disease and hemophilia, have a much
lower incidence of IBD than expected. The clinical results and other supporting
studies discussed above provide a strong rationale for the use of an ultra-low
molecular weight heparin such as OP2000 in the treatment of flares of IBD.
OP2000 is a product of the chemical cleavage of heparin, and has the
comparatively low molecular weight of 2,500 daltons, compared with full-length
heparin's molecular weight of about 14,000 daltons and other low molecular
weight heparin's molecular weight of 4,000 to 6,000 daltons. Lower molecular
weight, or smaller molecules of heparin, might prove to have advantages over
heparin itself, including better safety, efficacy and convenience. OP2000 has
been shown to be a potent anti-clotting agent. Like low molecular weight
heparins, and unlike heparin, routine monitoring of clotting factors during
treatment should not be necessary, providing a substantial advantage over
heparin. OP2000 has a longer lifetime in the body than heparin or low molecular
weight heparins and initial results indicate that OP2000 can be given in once-
daily injections under the skin. A key objective of Incara is to have OP2000 be
the first heparin-related product to obtain regulatory approval to treat
ulcerative colitis in the United States. The composition of OP2000 is covered
by claims of patents issued to Opocrin in the United States and Europe. We have
licensed OP2000 from Opocrin for all uses worldwide, except in Japan and Korea.
Clinical Development Program
We completed two Phase 1 clinical trials for OP2000, the most recent having
been completed in April 2000. These trials looked at single and multiple dose
administrations of the drug, and preliminary results indicate that we will be
able to give OP2000 on a once-a-day basis. OP2000 has been studied for another
indication in over 150 healthy subjects and patients in Europe with no
significant unexpected side effects. Assuming we have adequate financial
resources, we plan to begin a Phase 2/3 safety and efficacy trial in ulcerative
colitis patients by early 2001. If the results of the Phase 2/3 trial are
positive, we plan to conduct a confirmatory Phase 3 safety and efficacy trial
in ulcerative colitis and additional clinical studies of OP2000 blood levels
and other laboratory measurements. We would also consider a pilot study in
Crohn's disease. Our clinical scientists will manage the trials, including all
data collection and analysis activities.
Commercialization
Because of the relatively large number of patients suffering from
inflammatory bowel disease both in the United States and abroad, effectively
marketing a pharmaceutical for treatment of this indication requires the
resources of a large sales organization. We intend to seek development and
marketing relationships or licensing arrangements for OP2000 with
pharmaceutical companies with an established marketing presence in the
gastrointestinal field.
Human Liver Precursor Cell Transplant
Hepatic precursor cells are cells in the liver that can differentiate into a
variety of daughter cells that provide liver function. These are the early
cells in the maturation of the liver and include the liver stem cells and their
descendants. We are developing human liver precursor cells for use in the
treatment of liver failure.
5
Incara established its liver precursor cell program with the acquisition of
a majority ownership interest in Renaissance Cell Technologies, Inc. in
September 1997. Renaissance was founded in 1995 to commercialize applications
from research on human liver precursor cells from the laboratory of Dr. Lola
Reid, previously at the Albert Einstein College of Medicine and now a Professor
in the Department of Cell and Molecular Physiology, Program in Molecular
Biology and Biotechnology, at the University of North Carolina at Chapel Hill
School of Medicine. In March 2000, Incara acquired the remaining minority
interest of Renaissance, which is now a wholly owned subsidiary of Incara.
Liver Disease
The liver is one of the largest and most complex organs in the body, serving
many critical metabolic functions. More than most other organs, the liver has
the ability to regenerate itself by repairing or replacing injured tissue.
Despite this protection, once a critical mass of liver cells has died through
disease or damage, the liver can fail, leading to illness and death. Liver
failure is a serious health problem. Each year, there are an estimated 300,000
hospitalizations and 30,000 deaths in the United States due to chronic liver
diseases.
Currently, the only cure for many of these liver diseases is a liver
transplant. However, only about 4,800 donor livers become available each year
in the United States and the total cost of transplantation and first year
follow-up is estimated to average over $300,000. Over 16,500 patients are on
the liver transplant waiting list, an increase of more than 90% over the last
three years and up from 1,000 ten years ago. Furthermore, there are a total of
approximately 100,000 adults with severe cirrhosis and other forms of chronic
liver failure in the United States who could become candidates for a
transplant. Not all of these people will get transplants, or even get onto the
transplant waiting list. The incidence of chronic liver failure is expected to
increase in the next ten years as a result of the "silent epidemic" of
hepatitis C. Up to 4 million people in the United States are currently infected
with the hepatitis C virus. Researchers estimate that 15% of these persons will
develop cirrhosis, a disease that typically develops over a period of 10 to 20
years.
As a result of the shortage of donor organs, potential liver transplant
patients must wait, often for years, for a donor liver to become available. The
vast majority of patients with liver diseases therefore cannot rely on organ
transplantation as a solution. To bridge the gap between supply and demand for
liver donors, several companies are investigating the use of pig livers and pig
liver cells, as well as mature human liver cells and human cells derived from
tumors housed in a bioartificial liver to support an individual on a short-term
basis. These approaches, however, present a variety of scientific and medical
problems, including the risk of contamination from animal viruses. We believe
there is an urgent need for new technologies to support patients with damaged
livers, both acutely and long-term.
Liver Cell Transplantation
The ability to transplant cells that have the capacity to reproduce and
function in an impaired liver could reduce the need for whole organ transplants
and provide treatment for thousands of patients. In this procedure, a physician
injects a suspension of donor liver cells, or hepatocytes, into blood vessels
leading to the patient's liver or spleen. The transplanted cells take up
residence in the recipient's body and provide liver functions, including
detoxification and protein synthesis.
Positive results from liver cell transplants in rodents, both with mature
liver cells and precursor liver cells, have prompted physicians outside of
Incara to perform transplantation of unfractionated human hepatocytes (liver
cells not separated by their stage of maturity or other parameters) in a number
of human patients with encouraging results. Unfractionated human hepatocytes,
obtained from livers rejected for transplant use, have been introduced into
over 30 patients, with beneficial results often observed. These include
patients with cirrhosis, metabolic disorders and severe liver failure. Some
patients whose liver failure resulted in a coma, awoke after receiving liver
cell transplant, coincident with a decrease in ammonia levels, improved
cerebral blood flow and reduction of intracranial pressure. In one patient, a
10-year-old girl, the transplanted liver cells
6
survived and partially corrected a metabolic disorder for over 22 months.
Treatment by liver cell transplantation, however, has been limited because of
the lack of available organs from which viable liver cells can be obtained.
Human Liver Precursor Cells
Incara proposes to advance the present state of liver cell transplantation
by isolating, processing and transplanting human liver precursor cells. Human
liver precursor cells, unlike mature liver cells, can divide many times,
greatly expanding the utility of a single donor liver such that one liver could
supply the needs of many patients. Moreover, precursor cells might provide a
much longer functional life, potentially surviving the lifetime of the
recipient. These cells also can survive freezing and thawing better than
unfractionated cells, permitting precursors to be stored until the need for
them arises. The precursor cells should have the capability to differentiate
into the entire lineage of liver cells, providing the functions of early cells
that may be missing and unable to be regenerated by injection of unfractionated
hepatocytes. The precursor cells also might require less immunosuppression
drugs to prevent rejection of the new cells and a smaller injection volume than
that of unfractionated cells. The human liver precursors also avoid some of the
medical and scientific challenges associated with strategies involving pig
livers, pig liver cells and human cells derived from tumors.
Use of Alternative Sources of Donor Livers
Currently, most whole organ liver transplantation procedures require a donor
who has undergone brain death, but whose heart is still beating. This occurs
only in approximately one to two percent of hospital deaths, severely limiting
the potential donor pool.
Dr. Reid has demonstrated that viable liver precursor cells can be isolated
after death from the livers of non-beating-heart donors, whose livers cannot be
used for whole organ transplant. A major advantage of liver precursor cells is
their ability to survive periods with limited oxygen. The window of time that
viable liver precursors can be isolated after death is now under investigation,
along with the useful age range of donors. Because liver precursor cells can be
purified from livers inappropriate for transplant, our program will not compete
for organs with existing liver transplant programs. We have established an
arrangement with a traditional organ donor program for procurement of livers
from non-beating-heart donors. Preclinical experiments suggest that one donor
liver might provide enough liver precursor cells for many recipients.
Development Strategy
We are now scaling-up the liver precursor cell isolation and selection
process to produce the cells required for clinical trials. This step includes
establishing isolation and processing procedures needed for a 1,500-gram to
3,000-gram whole human liver instead of the 100-gram portions of liver used in
the basic research stage of the program. The scaled-up procedures are being
adapted for a sterile good manufacturing practices, or cGMP, environment. After
scale-up, we expect to transfer the liver precursor cell processing procedure
to a contract cell processor with a facility compliant with cGMP to produce
cells suitable for use in clinical trials.
Clinical Trials
Incara is exploring two patient populations for the initial clinical trials
of precursor cell transplantation. The first group consists of infants who are
too young for liver transplants and have life-threatening inherited genetic
diseases. This patient population represents a group with limited treatment
alternatives where improvement in patient condition and production of the
missing gene products would demonstrate the function of the transplanted cells.
The other series of clinical trials being planned targets the approximately
100,000 adults in the United States with such severe cirrhosis and other forms
of chronic liver failure that they could become candidates for a transplant.
Initially, these patients would receive the same immunosuppression as liver
transplant patients to prevent rejection of the transplanted cells. Assuming we
have adequate financial resources, Incara plans to begin these initial Phase 1
clinical trials in 2001. Clinical investigators from several
7
leading research hospitals have expressed interest in participating in our
clinical trials. Some of these investigators have experience with cell
transplants using unfractionated human liver cells and bioartificial livers and
believe the strategy of transplanting liver precursor cells provides a better
rationale for hepatocyte transplants.
Gene Therapy
Many gene therapy clinical trial results have in general been disappointing
for both physicians and patients, often because of the inability of the
treatment to provide the patient with the ability to sustain expression of the
inserted gene. Precursor cells, because of their extensive expansion potential,
represent a promising cell population to produce continued gene expression.
Incara's gene therapy strategy will be to insert into the liver precursor cells
a correct copy of a gene deficient in the patient and transplant these cells
into the patient. Logical target disorders are diseases resulting from the
inability of the patient's liver cells to properly make an important protein,
such as the missing LDL receptors in hypercholesterolemia and clotting factors
in hemophilia.
Genomics and Research Applications
The liver precursor cell technology developed by Incara has application as a
tool for identifying new drugs and in the drug development and testing process.
The liver precursor cells can be made to grow and differentiate into mature
liver cells. Determining gene expression patterns at various stages of the
liver lineage provides genomic information for drug discovery. For example,
this information can be used to identify new targets for drug discovery
programs or to identify proteins performing biological functions that may have
applications in therapy.
As a tool for the drug testing and development process, the liver precursor
cells and their daughter cells could be used to assess changes in gene
expression patterns caused by drugs being considered for development. The
changes in gene expression pattern from potential drugs could be compared with
those caused by drugs known to damage the liver. This would allow a
pharmaceutical company to screen compounds for their effect on the liver
earlier in the development process, saving time and money. The full lineage of
liver cells, from precursors to mature cells, could also be used to test drugs
for toxicity to the liver and to study how the drug is metabolized. Currently,
pharmaceutical companies have difficulty obtaining a consistent supply of human
liver cells for toxicity testing.
Liver Assist Device
Incara's liver precursor cell technology has application in the development
of a liver assist device, or LAD. For seven to thirty days, a LAD provides
liver function to allow a patient's own liver to recover from failure or to
provide a bridge to transplant. Incara's LAD is expected to be an artificial
liver composed of human liver cells in a device through which the patient's
blood or plasma is circulated.
Attempts at clinically useful LADs by others have utilized pig hepatocytes
or human liver cells derived from tumors in a wide variety of bioreactor types.
These devices have shown promise, but all use cells with limitations that our
LAD is designed to overcome. The pig hepatocytes, while easily obtained, have
severe limitations such as potential immune reactions to secreted pig proteins,
limited lifetime and non-human viruses. The liver cells derived from tumor
cells are easy to grow, but retain only a subset of the functions of normal
liver cells and involve safety concerns. Functioning human liver cells from
donor organs have not been an alternative due to the scarcity of donor livers.
We believe that a LAD using our human liver precursor cells could overcome
many of the problems experienced to date. Proteins secreted by these cells will
be of human origin so immune reactions should be minimized. The precursor cells
can divide extensively in culture so that cells from one donor liver may be
able
8
to supply many LADs. Most importantly, these cells should display the wide
range of liver functions necessary for clinical utility.
Commercialization
There are approximately 120 liver transplant programs in hospitals in the
United States. We believe that marketing to these hospitals could be
accomplished by an internal sales force of approximately 15 trained
specialists. We intend to maintain rights to market the liver precursor cell
transplantation therapy in the United States and develop a focused marketing
effort following establishment of the safety and efficacy of the program in
clinical trials. Outside of the United States, we expect to seek an arrangement
with another pharmaceutical or biotechnology company for commercialization of
the liver precursor cell therapy program. We also intend to seek arrangements
for the development of our liver precursor cells in gene therapy, drug research
and genomic applications and for use in a liver assist device.
Catalytic Antioxidant Small Molecule Program
Incara established its catalytic antioxidant program with the acquisition of
a majority interest in Aeolus Pharmaceuticals, Inc. in July 1995. In March
2000, Incara acquired the remaining minority interest in Aeolus, which is now a
wholly owned subsidiary of Incara. The scientific founders of Aeolus, James D.
Crapo, M.D., and Irwin Fridovich, Ph.D., in collaboration with colleagues at
Duke University, the National Jewish Medical and Research Center and Incara,
are working to develop small molecules as therapeutics that act in the same
manner as naturally occurring antioxidant enzymes. Antioxidant enzymes such as
superoxide dismutase normally protect the body from harmful free radicals.
Incara has obtained from Duke University and the National Jewish Medical and
Research Center the right to license the products developed by Drs. Crapo and
Fridovich in exchange for the payment of costs associated with the research, as
well as royalties on sales of the licensed products.
Antioxidants and Disease
Oxygen plays a pivotal role in supporting life by enabling energy stored in
food to be converted to energy that living organisms can use. The ability of
oxygen to participate in key metabolic processes derives from its highly
reactive nature. This reactivity is necessary for life, but also causes oxygen
to react harmfully with living organisms. In the body, oxygen is converted to
various free radicals, which can then damage DNA, proteins and lipids. The
cumulative result of these reactions is reduced cellular function and,
ultimately, disease. Free radicals are thought to play a role in a wide variety
of conditions, including chronic bronchitis, stroke, asthma, reperfusion injury
following heart attack, rheumatoid arthritis, Alzheimer's disease, Parkinson's
disease and even aging itself.
The enzyme SOD plays a critical role in protecting the body against attack
by free radicals. However, the natural enzyme's high molecular weight, short
half-life in circulation, inability to penetrate cells and high cost of
production limit its usefulness as a drug. In the 1980's and 1990's numerous
attempts by many pharmaceutical companies to develop forms of the SOD enzyme
failed to demonstrate the expected efficacy.
Incara has synthesized a group of small molecules that have multiple potent
catalytic antioxidant activities, destroy free radicals and protect cell
membranes. Catalytic antioxidants, unlike other antioxidants, function like
enzymes and are not consumed by their reaction with free radicals. Therefore,
they can destroy many free radicals. In laboratory experiments some of these
compounds have shown antioxidant activities greater than the natural SOD
enzymes on a weight basis. The lead compounds in this series, AEOL 10113 and
AEOL 10150, have shown promising activity in preclinical models of stroke and
heart attack. We also have a number of additional compounds available in this
series.
9
Stroke
An estimated 500,000 to 700,000 people in the United States annually suffer
strokes, about 400,000 of which are first-time strokes that occur essentially
without warning. In the United States, strokes kill approximately 158,000
people annually and have left more than one million people disabled to some
extent, according to the American Heart Association. The estimated direct cost
of stroke is over $40 billion annually, much of which is attributable to the
high expense of rehabilitating and caring for victims.
Stroke is an injury to the brain caused by the blockage of blood flow. The
reestablishment of blood flow after blockage can cause further damage, which is
called reperfusion injury. Many scientists believe that the damage from stoke
and reperfusion injury might be caused, at least in part, by free radicals. In
a model of stroke, where the middle cerebral artery of a rat is blocked for 90
minutes and then unblocked, AEOL 10113 significantly reduced damaged brain
tissue when introduced as late as 7 1/2 hours after the start of the stroke.
AEOL 10150 significantly reduced damaged brain tissue in a mouse model of
severe stroke in which blood flow to a portion of the brain was permanently
blocked.
We expect to complete the following activities prior to initiating Phase 1
clinical trials:
. Scale-up manufacturing of drug candidate;
. Analytical/bioanalytical methods development and validation;
. Formulation development;
. Manufacture and release of preclinical and clinical supplies; and
. Additional toxicology studies, through two-week exposure in two species.
Assuming we have adequate financial resources and satisfactory completion of
the preclinical studies, we intend to initiate Phase 1 clinical trials in 2001.
Heart Attack
Acute myocardial infarction, commonly called a heart attack, is the death of
heart tissue that results from interruption of blood flow through one or more
coronary blood vessels to portions of the heart. Prolonged or permanent
interruption of blood flow deprives a portion of the heart of oxygen,
eventually leading to death of heart muscle cells. If blood flow is
reestablished quickly, either spontaneously or through medical intervention,
the damage can be reversed or reduced. However, reestablishment of blood flow
to heart muscle cells can also cause injury to these or neighboring cells. This
injury is called ischemia reperfusion injury.
Research suggests that free radicals play an important role both in the
damage caused by interruption of blood flow and the damage associated with
ischemia reperfusion injury. Antioxidants, therefore, might offer benefit to
heart attack patients by reducing tissue injury. Preliminary studies in animal
model systems suggest that AEOL 10113 could reduce damage caused by heart
attacks. Additional studies are underway to confirm these observations.
According to the American Heart Association, approximately 1.1 million
people in the United States have heart attacks each year, 40% of whom die
within a year. More than half of these deaths occur after the patient arrives
at the hospital. Survivors often experience other serious health problems
resulting from the heart attack such as chronic congestive heart failure.
Medical intervention that reduces the damage caused by heart attack might save
lives and reduce suffering.
Commercialization
Because of the large numbers of patients suffering from stroke and heart
attack, effectively marketing a pharmaceutical for treatment of these
indications requires the resources of a large sales organization. We intend
10
to seek development, marketing or licensing arrangements for the stroke and
heart attack indications of our antioxidant program with pharmaceutical
companies with an established marketing presence in the target indications.
Collaborative and Licensing Arrangements
Our strategy is to develop and add value to both in-licensed products and
sponsored research programs and, once a product appears viable, to enter into
collaborations and licensing agreements for manufacturing and marketing. All of
our product development programs rely on licenses of technology from third
parties, as described below.
Opocrin License
In July 1998, we signed a 15-year agreement with Opocrin to obtain the
exclusive rights to OP2000 on a worldwide basis, except for Japan and Korea. We
paid $1,000,000 to Opocrin as a license fee upon execution of the agreement.
Additional compensation will be payable to Opocrin upon initiation of specified
clinical trials, upon filing for specified regulatory approval, upon obtaining
specified regulatory approval, and upon achieving specified aggregate annual
sales. Incara also is to pay Opocrin royalties on net sales and is responsible
for the costs of conducting clinical trials for OP2000. Incara and Opocrin have
agreed to diligently pursue the negotiation and execution of a manufacturing
supply agreement, under which Opocrin would manufacture OP2000 for commercial
purposes.
University of North Carolina License
We have a sponsored research agreement which covers research at the
University of North Carolina by scientists in the area of hepatic stem cells.
This agreement grants us the first option to obtain an exclusive license to
inventions resulting from the research during the term of the research
agreement, or during the one-year period following termination of the
agreement. The research aspect of the agreement with UNC can be terminated by
mutual consent or on 12 months' written notice by either party. In August 1999,
we obtained an exclusive worldwide license from UNC to make, use and sell
products using proprietary information and technology developed under this
sponsored research agreement. The UNC license includes rights to five U.S.
patent applications filed during 1999 and 2000, including patent applications
for isolating and purifying human liver precursor cells. We are pursuing
international patent protection, as we deem appropriate. We will make milestone
payments to UNC upon the occurrence of development milestones and royalties on
net sales. We are also obligated to pay patent filing, prosecution, maintenance
and defense costs.
Albert Einstein College of Medicine
We have obtained exclusive worldwide rights from Albert Einstein College of
Medicine for patents resulting from research conducted on liver stem and
precursor cells by Dr. Reid and other scientists, while Dr. Reid was at
Einstein. The United States component of this patent portfolio includes four
issued patents, and three pending patent applications. We also have two pending
patent applications in each of Europe and Japan.
Incara must pay royalties to Einstein on net product sales during the term
of the licenses and must pay minimum royalties beginning in 2004. We also must
pay patent prosecution, maintenance and defense costs. The Einstein licenses
are terminable in the event of breach, and otherwise expire when the last
licensed patent expires.
Duke Licenses
We have obtained exclusive worldwide rights from Duke University to products
using antioxidant technology and compounds developed by Dr. Irwin Fridovich and
other scientists at Duke. These scientists provide research support and advice
in the field of free radical and antioxidant research. Further discoveries in
11
the field of antioxidant research from these scientists' laboratories at Duke
also are covered by the licenses from Duke.
Incara must pay royalties to Duke on net product sales during the term of
the Duke licenses, and payments upon the occurrence of development milestones.
In addition, we are obligated under the Duke license to pay patent prosecution,
maintenance and defense costs. The Duke licenses are terminable in the event of
breach and otherwise expire when the last licensed patent expires.
National Jewish License
In September 1997, Aeolus executed a Sponsored Research Agreement with
National Jewish Medical and Research Center. The National Jewish Agreement
grants Aeolus an option to negotiate a royalty-bearing exclusive license for
technology, patents and inventions resulting from research at National Jewish
within the field of antioxidant compounds and related discoveries. Aeolus has
agreed to support National Jewish's costs incurred in performance of the
research. In November 2000, we obtained an exclusive worldwide license from
National Jewish to develop, make, use and sell products using proprietary
information and technology developed under this sponsored research agreement.
We will make milestone payments to National Jewish upon the occurrence of
development milestones and pay royalties on net sales. We are also obligated to
pay patent filing, prosecution, maintenance and defense costs.
Manufacturing and Marketing
Our strategy is to contract with third parties for manufacturing
capabilities that we cannot establish in a cost-effective manner. Our most
advanced product, OP2000, is being manufactured for clinical trials for us in
bulk form by Opocrin, the licensor of that product, on a cost-plus basis.
Incara and Opocrin have agreed to diligently pursue the negotiation and
execution of a manufacturing supply agreement, under which Opocrin would
manufacture OP2000 for commercial purposes.
We have identified and are in discussions with third parties to conduct the
cell processing for hepatic precursor cells being developed by Incara. To begin
clinical trials, we must contract with a supplier to isolate the hepatic
precursor cells in compliance with cGMP regulations. We have not yet
established the terms of any supply arrangement, and we might not be able to
enter into any third party arrangements on satisfactory terms. We also must
establish and maintain sources of livers or liver tissues from which the
precursor cells can be isolated. We have historically relied on several
suppliers of liver tissues for research, but entering into the clinical trial
stage of development will increase our needs. For clinical trials and
ultimately for commercialization, we plan to obtain, from the traditional organ
transplant donor programs, livers that are not suitable for full liver
transplant.
We have identified a potential manufacturer of clinical products for the
catalytic antioxidants being developed, but we have not yet negotiated the
terms of clinical supply.
Because some of our potential products are being developed for large
therapeutic markets requiring broad sales and marketing capabilities, we expect
to contract with larger pharmaceutical companies to obtain the needed reach of
a large sales force for these products. This could include OP2000 and products
resulting from our antioxidant program and the international marketing of all
of our products. We have not identified who will market our ongoing product
development programs. We might not be able to enter into any marketing
arrangements on satisfactory terms.
We might choose to establish our own marketing capabilities for product
areas where we consider a targeted marketing effort appropriate. This could
include the liver precursor cell program, which we believe would target the
approximately 120 liver transplant centers in the United States. Establishing
marketing capabilities could require substantial funds and we might not
successfully establish our own marketing capabilities on a cost-effective basis
or at all.
12
Competition
General
Competition in the pharmaceutical industry is intense and we expect it to
increase. Technological developments in our fields of research and development
occur at a rapid rate and we expect competition to intensify as advances in
these fields are made. We will be required to continue to devote substantial
resources and efforts to research and development activities. Our most
significant competitors are fully integrated pharmaceutical companies and more
established biotechnology companies, which have substantially greater
financial, technical, sales and marketing, and human resources than us. These
companies might succeed in obtaining regulatory approval for competitive
products more rapidly than we can for our products. In addition, competitors
might develop technologies and products that are cheaper, safer or more
effective than those being developed by us or that would render our technology
obsolete.
We expect that important competitive factors in our potential product
markets will be the relative speed with which we and other companies can
develop products, complete the clinical testing and approval processes, and
supply commercial quantities of competitive product(s) to the market. With
respect to clinical testing, competition might result in a scarcity of clinical
investigators and patients available to test our potential products, which
could delay development.
As described below, we are aware of products in research or development by
our competitors that address the diseases being targeted by us.
Inflammatory Bowel Disease
The two major forms of inflammatory bowel disease, ulcerative colitis and
Crohn's disease, are treated by antidiarrheals, steroids, other anti-
inflammatory drugs and immunosuppressants. Crohn's disease also is being
treated by off-label use of metronidazole, an antibiotic that acts as an anti-
inflammatory through an unknown mechanism. Some of the drugs used to treat
these diseases are available in generic form and are being marketed at a price
that could be less than the price of OP2000, if it were successfully developed
and approved. Low molecular weight heparins are approved for non-IBD
indications and marketed by others, who might try to develop their low
molecular weight heparins for IBD.
Remicade(R) was approved by the FDA in 1998 for use in treating moderately
to severely active Crohn's disease. Remicade is an antibody indicated for the
reduction of the signs and symptoms of Crohn's disease in patients who have an
inadequate response to conventional therapy. The drug is being marketed in the
United States by Centocor, Inc. Its cost and the concern over possible allergic
reaction to the protein, however, have limited its use in this indication.
Hepatic Diseases
We are aware of competitive efforts in academic, research and commercial
institutions using human hepatic cells in treatment of liver disease. Tissue
Transformation Technologies, Inc. and Diacrin, Inc. are conducting Phase 1
clinical trials for treatment of cirrhosis using human liver cell transplants.
In addition, other companies and academic laboratories are investigating the
use of pig livers in transplantation as a substitute for human liver and the
use of hepatocytes prepared from pig livers as a form of cell therapy. Several
other companies have conducted research and development on a bioartificial
liver device to treat acute liver failure that could be competitive with our
technology under development. In particular, Circe Biomedical, Inc. has
conducted clinical trials with a bioartificial liver that uses pig liver cells,
and VitaGen Incorporated is conducting a clinical trial with a bioartificial
liver that utilizes human liver cells derived from tumors. At least one company
is pursuing the growth of mini-organs, including liver. StemCells, Inc.,
formerly Cytotherapeutics, Inc., and other corporations and academic
institutions are conducting research in the area of liver and other organ stem
and precursor cells. Stem cell research in general is being developed by a
number of
13
companies, including Geron Corporation, which has announced that it has
isolated embryonic stem cells. In theory, embryonic stem cells could have the
capacity to differentiate into all human systems, including the liver.
Antioxidants
Several companies have explored the therapeutic potential of antioxidant
compounds in numerous indications. Historically, most of these companies have
focused on engineered versions of naturally occurring antioxidant enzymes, but
with limited success, perhaps because the large size of these molecules makes
delivery into the cells difficult. Antioxidant drug research continues at a
rapid pace despite previous clinical setbacks. In October 1998, Metaphore
Pharmaceuticals Inc. reported results from preclinical studies of a small
molecule that performs the same chemical reactions as the antioxidant enzyme
superoxide dismutase (SOD). Metaphore reported that this compound substantially
reduced tissue damage due to inflammation and reperfusion in animal models.
Eukarion, Inc. is also developing similar compounds, which are in preclinical
development for conditions associated with damage caused by free radicals.
AstraZeneca is developing a nitrone compound with free radical trapping
properties for stroke. The compound, licensed from Centaur Pharmaceuticals, is
currently in Phase 2 development.
Patents and Proprietary Rights
We generally seek patent protection in the United States and other
jurisdictions for potential products and proprietary technology, including
products and technology licensed from third parties. The process for preparing
and prosecuting patents is lengthy, uncertain and costly. Patents might not
issue on any of the pending patent applications owned or licensed by us from
third parties. Even if patents issue, the claims allowed might not be
sufficiently broad to protect our technology or provide us protection against
competitive products or otherwise be commercially valuable. Patents issued to
or licensed by us could be challenged, invalidated, infringed, circumvented or
held unenforceable. Even if we successfully defend our patents, the costs of
defense can be significant.
We have the exclusive license from Opocrin, in all countries other than
Japan and Korea, for an issued patent to develop and commercialize OP2000. We
also have a non-exclusive license from Opocrin to practice related patents, to
the extent required for our activities related to OP2000. We are aware of a
recently issued patent claiming the use of fractions of heparin for the
treatment of inflammatory bowel disease. We do not believe the development of
OP2000 will require the licensing of this patent. If OP2000 were to be
determined to fall within the scope of this patent and if the patent's claims
were found to be valid, we would have to license this patent in order to
commercialize OP2000. We might not be able to license this patent at a
reasonable cost which would result in our not being able to market OP2000.
Uncertainty regarding the scope or validity of this patent might deter
companies from collaborating with us for the development and commercialization
of OP2000.
In the liver precursor cell program, we have an exclusive license for four
issued United States patents and three pending patent applications from Albert
Einstein College of Medicine. Claims included in these issued patents include
an isolated hepatocyte precursor capable of differentiating into a hepatocyte
and a population of genetically engineered hepatocyte precursor cells. We also
have two related pending patent applications in each of Europe and Japan. Our
UNC sponsored research agreement allows us to obtain an exclusive worldwide
license to make, use and sell products using proprietary information and
technology developed under the UNC sponsored research agreement. Rights to five
U.S. patent applications filed during 1999 and 2000 are currently included in
the UNC license, as well as appropriate related international applications.
Pending claims on the UNC patents include human liver precursor cell
composition and process for their isolation, expansion and cryopreservation and
the use of non-beating-heart donors as a source for precursor cells.
Our catalytic antioxidant small molecule technology base is described in
four issued U.S. patents and five patent applications that are pending. These
patents and patent applications belong in whole or in part to Duke
14
or National Jewish and are licensed to us. These patents and patent
applications cover soluble manganic porphyrins as antioxidant molecules as well
as targeted compounds obtained by coupling such antioxidant compounds to
molecules that bind to specific extracellular elements. The pending U.S.
applications include composition of matter claims for several series of
compounds. Corresponding international patent applications have been filed, one
of which has issued.
In addition to patent protection, we rely upon trade secrets, proprietary
know-how and technological advances that we seek to protect in part through
confidentiality agreements with our collaborative partners, employees and
consultants. Our employees and consultants are required to enter into
agreements providing for confidentiality and the assignment of rights to
inventions made by them while in our service. We also enter into non-disclosure
agreements to protect our confidential information furnished to third parties
for research and other purposes. These types of agreements can be difficult to
enforce and for some types of breach there is no satisfactory remedy for
unauthorized disclosures. It is possible that our trade secrets and proprietary
know-how will become known or will be independently discovered by others
despite our efforts.
Our commercial success will also depend in part on our ability to
commercialize products without infringing patents or other proprietary rights
of others or breaching the licenses granted to us. If we are not able to obtain
a license to any third-party technology needed for our business at a reasonable
cost, we might have to stop developing the product.
As with any pharmaceutical company, our patent and other proprietary rights
are uncertain. The patent rights related to our products might conflict with
current or future proprietary rights of others. For the same reasons the
products of others could infringe our patent or proprietary rights. Litigation
or patent interference proceedings, either of which could result in substantial
cost, might be necessary to enforce any patents or other proprietary rights
issued to us or to determine the scope and validity or enforceability of other
parties' proprietary rights. The defense and prosecution of patent and
intellectual property claims are both costly and time consuming, even if the
outcome is favorable to us. Any adverse outcome could make us pay damages to
third parties, require disputed rights to be licensed from third parties, or
require us to cease selling our products.
Government Regulation
Our research and development activities and the manufacturing and marketing
of our future products are subject to regulation by numerous governmental
agencies in the United States and in other countries. The FDA and comparable
agencies in other countries impose mandatory procedures and standards for the
conduct of clinical trials and the production and marketing of products for
diagnostic and human therapeutic use. Before obtaining regulatory approvals for
the commercial sale of any of our products under development, we must
demonstrate through preclinical studies and clinical trials that the product is
safe and efficacious for use in each target indication. The results from
preclinical studies and early clinical trials might not be predictive of
results that will be obtained in large-scale testing. Our clinical trials may
not successfully demonstrate the safety and efficacy of any products or result
in marketable products.
The steps required by the FDA before new drug or cell therapy products may
be marketed in the United States include:
. preclinical studies;
. the submission to the FDA of a request for authorization to conduct
clinical trials on an investigational new drug or cell therapy, which
must become effective before human clinical trials may commence;
. adequate and well-controlled human clinical trials to establish the
safety and efficacy of the drug or cell therapy for its intended use;
. submission to the FDA of a New Drug Application, or NDA, for a drug, or
submission to the FDA of a Biological License Application, or BLA, in the
case of a cell therapy; and
15
. review and approval of the NDA or BLA by the FDA before the product may
be shipped or sold commercially.
In addition to obtaining FDA approval for each product, each manufacturing
and cell processing establishment must be registered with the FDA and undergo
an inspection prior to the approval of an NDA or BLA. Each manufacturing
facility, and its quality control and manufacturing procedures must also
conform and adhere at all times to the FDA's cGMP regulations. In addition to
preapproval inspections, the FDA and other government agencies regularly
inspect manufacturing facilities for compliance with these requirements.
Manufacturers must expend time, money and effort in the area of production and
quality control to ensure full technical compliance with these standards.
Preclinical testing includes laboratory evaluation and characterization of
the safety and efficacy of a drug or cell therapy and its formulation.
Preclinical testing results are submitted to the FDA as a part of an
Investigational New Drug Application, or IND, which must become effective prior
to commencement of human clinical trials. Clinical trials are typically
conducted in three sequential phases following submission of an IND. Phase 1
represents the initial administration of the drug or cell therapy to a small
group of humans, either patients or healthy volunteers, typically to test for
safety (adverse effects), dosage tolerance, absorption, distribution,
metabolism, excretion and clinical pharmacology, and, if possible, to gain
early evidence of effectiveness. Phase 2 involves studies in a small sample of
the actual intended patient population to assess the efficacy of the drug or
cell therapy for a specific indication, to determine dose tolerance and the
optimal dose range and to gather additional information relating to safety and
potential adverse effects. Once an investigational drug or cell therapy is
found to have some efficacy and an acceptable safety profile in the targeted
patient population, Phase 3 studies are initiated to further establish clinical
safety and efficacy of the therapy in a broader sample of the general patient
population, in order to determine the overall risk-benefit ratio of the drug or
cell therapy and to provide an adequate basis for any physician labeling.
During all clinical studies, we must take care to adhere to good clinical
practice, or GCP, standards. The results of the research and product
development, manufacturing, preclinical studies, clinical studies and related
information are submitted in an NDA or BLA to the FDA.
The process of completing clinical testing and obtaining FDA approval for a
new drug or cell therapy product is likely to take a number of years and
require the expenditure of substantial resources. If an application is
submitted, there can be no assurance that the FDA will review and approve the
NDA or BLA. Even after initial FDA approval has been obtained, further studies,
including post-market studies, may be required to provide additional data on
safety and will be required to gain approval for the use of a product as a
treatment for clinical indications other than those for which the product was
initially tested. Also, the FDA will require post-market reporting and may
require surveillance programs to monitor the side effects of the drug or cell
therapy. Results of post-marketing programs may limit or expand the further
marketing of the products. Further, if there are any modifications to the drug
or cell therapy, including changes in indication, manufacturing process,
labeling or a change in manufacturing facility, an NDA or BLA supplement may be
required to be submitted to the FDA.
The rate of completion of our clinical trials will be dependent upon, among
other factors, the rate of patient enrollment. Patient enrollment is a function
of many factors, including the size of the patient population, the nature of
the trial, the availability of alternative therapies and drugs, the proximity
of patients to clinical sites and the eligibility criteria for the study.
Delays in planned patient enrollment may result in increased costs and delays,
which could have a material adverse effect on us.
Failure to comply with applicable FDA requirements may result in a number of
consequences that could materially and adversely affect us. Failure to adhere
to approved trial standards and GCPs in conducting clinical trials could cause
the FDA to place a clinical hold on one or more studies which would delay
research and data collection necessary for product approval. Noncompliance with
GCPs could also have a negative impact on FDA's evaluation of an NDA or BLA.
Failure to adhere to GMPs and other applicable requirements could result in FDA
enforcement action and in civil and criminal sanctions, including but not
limited to fines,
16
seizure of product, refusal of the FDA to approve product approval
applications, withdrawal of approved applications, and prosecution.
Whether or not FDA approval has been obtained, approval of a product by
regulatory authorities in foreign countries must be obtained prior to the
commencement of marketing of the product in such countries. The requirements
governing the conduct of clinical trials and product approvals vary widely from
country to country, and the time required for approval may be longer or shorter
than that required for FDA approval. Although there are some procedures for
unified filings for certain European countries, in general, each country at
this time has its own procedures and requirements. There can be no assurance
that any foreign approvals will be obtained.
In addition to the regulatory framework for product approvals, we and our
collaborative partners must comply with laws and regulations regarding
occupational safety, laboratory practices, the use, handling and disposition of
radioactive materials, environmental protection and hazardous substance
control, and other local, state, federal and foreign regulation. The impact of
such regulation upon us cannot be predicted and could be material and adverse.
Employees
As of November 30, 2000, we had 21 employees. None of our employees is
represented by a labor union. We consider our employee relations to be good. We
are highly dependent on the principal members of our management and scientific
staff. The loss of certain key employees could have a material adverse effect
on us. In addition, we believe that our future success will depend in large
part upon our ability to attract and retain highly skilled scientific and
managerial personnel. We face competition for such personnel from other
companies, research and academic institutions, government entities and other
organizations. We might not be successful in hiring or retaining the personnel
we require.
Discontinued Programs
Our historical cash expenditures prior to December 31, 1999 were
significantly higher than our current cash spending rate. This lower level of
expenditures has resulted from the discontinuation of the IRL and BEXTRA
programs.
IRL
On December 29, 1999, we completed the sale of Incara Research Laboratories,
or IRL, our anti-infective drug discovery division, to a subsidiary of Advanced
Medicine, Inc., a private pharmaceutical company, for a cash payment of
$11,000,000 and the right to receive future payments totaling up to an
additional $4,000,000 in the event a compound originating from the
collaboration with Merck & Co., Inc. reaches preclinical and clinical trial
milestones. We currently do not expect to receive additional payments from the
purchaser. The transaction involved the sale of assets associated with Incara's
anti-infective division, including rights under the collaboration agreement
with Merck, and the assumption of related liabilities by the purchaser.
Expenses for IRL were $1,339,000 and $8,245,000 for the fiscal years ended
September 30, 2000 and 1999, respectively. We do not expect any additional
expenses for IRL. As a result of the sale of IRL, we remain contingently liable
through May 2007 on debt and lease obligations assumed by the purchaser,
including the IRL facility lease in Cranbury, New Jersey. This contingent
liability was approximately $8,328,000 in September 2000 and should decline on
an approximately straight-line basis to zero in May 2007.
BEXTRA
Until July 1999, our most advanced product was BEXTRA (bucindolol HCl), a
beta-blocker that was being evaluated in a Phase 3 clinical trial conducted by
the National Institutes of Health and the United States Department of Veterans
Affairs for use in treating congestive heart failure patients. The study was
terminated
17
in July 1999 prior to its scheduled termination date based on an interim
analysis by the Data and Safety Monitoring Board that showed that treatment
with bucindolol did not demonstrate a statistically significant improvement in
survival in the patient population as a whole. Based on this result, we agreed
to end our collaboration with BASF Pharma/Knoll AG for BEXTRA for countries
outside the United States and Japan, and we terminated the European trial of
BEXTRA. We do not expect to pursue further development of the compound for this
or any other indication. The compound was being developed with Interneuron
Pharmaceuticals, Inc. through a jointly owned company named CPEC LLC. BEXTRA
related expenses were $6,469,000 for fiscal 1999.
Risks Associated with Our Business
You should carefully consider the risk factors discussed below, together
with all of the other information included in this Form 10-K and presented
elsewhere by us from time to time. If any of the following risks, or other
risks not known to us or that we currently believe to not be significant,
develop into actual events, then our business, financial condition, results of
operations or prospects could be materially adversely affected. If that
happens, the market price of our common stock could decline.
We will continue to incur substantial losses and we might never achieve a
profit.
As of September 30, 2000, we had an accumulated deficit of $83,907,000 from
our research, development and other activities. We have not generated any
revenues from product sales and do not expect to do so for several years, at
least. In the past, most of our revenues have come from collaborators who
reimbursed us for research and development activities. None of our current
activities are being funded by third parties at this time.
If we do not raise significant additional capital, we will be unable to fund
all of our research and development activities and will need to eliminate or
curtail these programs.
One of the most significant issues we face is adequate funding of our
existing projects. As of September 30, 2000, we had cash and investments of
$6,555,000. While we believe our existing financial resources are adequate to
fund operations through fiscal 2001, we intend to rely on a financing facility
we have with Torneaux Fund Ltd. or other financing arrangements to support a
higher level of research and development efforts during fiscal 2001.
Our financial requirements during 2001 and over the longer term will depend
upon the success of our research and development programs and our ability to
enter into new collaborations that provide fees and research and development
funding. If some or all of our programs continue to show scientific progress,
we will need significant additional funds to move compounds through the
preclinical stages and into clinical trials. If we are unable to raise the
amount of capital necessary to complete development and reach commercialization
of any of our therapeutic products, we will need to delay or cease development
of one or more of our products.
Stockholders might experience significant dilution from our issuance to
Torneaux Fund Ltd. of up to 2,940,332 shares, or 28.5% of the total number of
our shares which would then be outstanding, based on shares outstanding as of
November 30, 2000.
In August 2000, we entered into a financing arrangement with Torneaux Fund
Ltd. under which we will sell our common stock to Torneaux and also issue to
Torneaux warrants which are convertible into our common stock. The issuance of
up to 2,940,332 shares of our common stock to Torneaux under the common stock
purchase agreement and warrants will have a dilutive effect on our stockholders
of as much as 28.5% of the total number of shares which would then be
outstanding, based on the 7,365,849 shares of common stock outstanding on
November 30, 2000. The number of shares that we issue to Torneaux under the
agreement is based upon a discount to the daily weighted average market price
of our stock over a 20-day trading period. If and as the market price declines,
the number of shares which may be sold to Torneaux will increase. If we sell
shares to Torneaux at a time when our stock price is low, our stockholders
would be significantly diluted. In addition, the
18
perceived risk of dilution by Torneaux and our other stockholders might cause
them to sell their shares, which could further decrease the market price of our
shares. Torneaux's resale of our common stock will increase the number of our
publicly traded shares, which could also lower the market price of our common
stock.
The ownership interest of our stockholders will be substantially diluted by
future issuances of stock, including new offerings and exercises of currently
outstanding options and warrants.
As of November 30, 2000, Incara had 7,365,849 shares of common stock
outstanding. Options to purchase a total of 2,500,000 shares of Incara common
stock may be granted under the 1994 Stock Option Plan to our employees,
directors and consultants. As of November 30, 2000, options to purchase
1,941,160 shares at exercise prices ranging from $0.04 to $20.50, with a
weighted average exercise price of $3.09, and warrants to purchase 66,816
shares at exercise prices ranging from $8.25 to $13.49 were outstanding. In
addition, we have reserved 80,928 shares for issuance pursuant to our Employee
Stock Purchase Plan.
We intend to sell new shares of our common stock or preferred stock during
the next year to meet our capital requirements. All of these issuances of stock
will dilute the ownership interests of the existing stockholders. The threat of
dilution posed by shares available for future sale could reduce the market
price of our common stock and could make it more difficult for us to raise
funds through equity offerings in the future.
A return on your investment in our common stock will be dependent on an
increase in the price of our common stock, which has fluctuated between $0.50
and $11.00 in the last two years.
There is no set yield on our common stock. In addition, we do not currently
anticipate paying cash dividends on our common stock because we intend to
retain all earnings for the foreseeable future to fund our business operations.
As a result, anyone investing in our common stock must look to an increase in
its price to derive any value on their investment.
Our common stock is not actively traded and the price of our common stock has
fluctuated from $0.50 to $11.00 in the last two years; and the sale of shares
to Torneaux could cause our stock price to decline.
Our common stock is listed on the Nasdaq National Market System under the
symbol "INCR." The public market for our common stock has been characterized by
low and/or erratic trading volume, often resulting in price volatility. An
active public market for our common stock might be limited because of the small
number of shares outstanding, the limited number of investors and the small
market capitalization (which is less than that authorized for investment by
many institutional investors).
All 2,940,332 shares of our common stock that we might sell to Torneaux have
been registered for resale with the Securities and Exchange Commission and will
be freely tradable. The resale of a significant amount of shares issued to
Torneaux at any given time could cause the trading price of our common stock to
decline and to be highly volatile.
The market price of our common stock also is subject to wide fluctuations
due to factors that we can not control, including the results of preclinical
and clinical testing of our current products, decisions by collaborators
regarding product development, regulatory developments, market conditions in
the pharmaceutical and biotechnology industries, future announcements
concerning our competitors, adverse developments concerning proprietary rights,
public concern as to the safety or commercial value of our products, and
general economic conditions.
Furthermore, the stock market has experienced significant price and volume
fluctuation unrelated to the operating performance of particular companies.
These market fluctuations can adversely affect the market price and volatility
of our common stock.
19
Our research and development programs are at an early stage and therefore
might never develop viable products.
Our product programs are in the early stages of development, involve
unproven technology, require significant further research and development and
regulatory approvals, and are subject to the risks of failure inherent in the
development of products or therapeutic procedures based on innovative
technologies. These risks include the possibilities that any or all of these
proposed products or procedures are found to be unsafe or ineffective, or
otherwise fail to receive necessary regulatory approvals; that the proposed
products or procedures are uneconomical to market or do not achieve broad
market acceptance; that third parties hold proprietary rights that preclude us
from marketing them; or that third parties market a superior or equivalent
product. Further, the timeframes for commercialization of any products are long
and uncertain, because of the extended testing and regulatory review process
required before marketing approval can be obtained.
A failure to obtain or maintain patent and other intellectual property rights
would allow others to develop and sell products similar to ours, which could
impair our business.
The success of our business depends, in part, on our ability to establish
and maintain adequate protection for our intellectual property, whether owned
by us or licensed from third parties. We rely primarily on patents in the
United States and in other key markets to protect our intellectual property. If
we do not have patent protection, other companies could sell substantially
identical products as ours, without incurring any liability to us. Patent
prosecution, maintenance and enforcement on a global basis is expensive, and
many of these costs must be incurred before we know whether a product covered
by the claims will be successfully developed or marketed.
Even if we expend considerable time and money on prosecution, a patent
application might never issue as a patent. We can never be certain that we were
the first to invent the particular technology or that we were the first to file
a patent application for the technology, because United States patent
applications are maintained in secrecy until a patent issues. Publications in
the scientific or patent literature generally do not identify the date of an
invention, so it is possible that a competitor could be pursuing the same
invention and have an earlier invention date than ours.
Even if patents issue, the claims allowed might not be sufficiently broad to
protect our technology against competitive products. Patent protection differs
from country to country, giving rise to increased competition from other
products in countries where patent coverage is weak or not enforced. Once a
patent issues, we still face the risk that others will try to design around our
patent or will try to challenge or invalidate the patent. If a patent were
invalidated, we could be subject to significant liabilities to a third party,
be required to license the invention from a third party, or be prevented from
using the invention altogether. The cost of litigation can be substantial, even
if we prevail.
If a third party were to bring an infringement claim against us, we would
incur significant costs in our defense; if the claim were successful, we would
need to obtain licenses to develop non-infringing technology.
Our business also depends on our ability to develop and market products
without infringing patents or other proprietary rights of others and without
breaching the scope of the licenses related to our intellectual property. The
pharmaceutical industry is subject to frequent and protracted litigation
regarding patent and other intellectual property rights. Most companies have
numerous patents that protect their intellectual property rights. These third
parties might assert claims against us with respect to our product candidates
and future products. If litigation were required to determine the validity of a
third party's claims, we could spend significant resources and be distracted
from our core business activities, regardless of the outcome. If we did not
prevail in the litigation, we could be required to license a third party's
technology, which might not be possible on satisfactory terms, or discontinue
our own activities and develop non-infringing technology, any of which could
delay our development programs.
20
We have the exclusive license from Opocrin S.p.A., in all countries other
than Japan and Korea, to develop and market OP2000. This license is based on
an issued patent held by Opocrin claiming a heparin derivative with a
specified range of molecular weight. We also have a non-exclusive license from
Opocrin to practice certain related patents, to the extent required for our
activities related to OP2000. We are aware of a recently issued patent
claiming the use of certain fractions of heparin for the treatment of
inflammatory bowel disease. We do not believe the development of OP2000 will
require the licensing of this patent. If OP2000 were to be determined to fall
within the scope of this patent and if the patent's claims were found to be
valid, we would have to license this patent in order to commercialize OP2000.
We might not be able to license this patent at a reasonable cost which would
result in our not being able to market OP2000. Uncertainty regarding the scope
or validity of this patent might deter companies from collaborating with us
for the development and commercialization of OP2000.
Protection of trade secret and confidential information is difficult, and
loss of confidentiality could eliminate our competitive advantage.
In addition to patent protection, we rely on trade secrets, proprietary
know-how and confidential information to protect our technological advances.
We use confidentiality agreements with our employees, consultants and
collaborative partners to maintain the proprietary nature of this technology.
However, confidentiality agreements can be breached by the other party, which
would make our trade secrets and proprietary know-how available for use by
others. There is generally no adequate remedy for breach of confidentiality
obligations. In addition, the competitive advantage afforded by trade secrets
is limited because a third party can independently discover or develop
something identical to our own trade secrets or know-how, without liability to
us.
If our employees, consultants or collaborators were to use information
improperly obtained from others (even if unintentional), disputes could arise
as to ownership and rights in any resulting know-how or inventions.
Our research and development programs rely on technology licensed from third
parties, and termination of any of those licenses would result in loss of
significant rights to develop and market our products, which would impair our
business.
We have exclusive worldwide rights to our antioxidant small molecule
technology through license agreements with Duke University and National Jewish
Medical Center. We also have the worldwide exclusive rights to patents
licensed from Albert Einstein College of Medicine and patent applications and
rights to license future technology arising out of research sponsored at the
University of North Carolina at Chapel Hill (related to the liver precursor
cell program) and National Jewish Medical Center (related to antioxidant small
molecules). Key financial and other terms, such as royalty payments, for the
licensing of this future technology would still need to be negotiated with the
research institutions, and it might not be possible to obtain any such license
on terms that are satisfactory to us.
Our licenses generally may be terminated by the licensor if we fail to
perform our obligations, including obligations to develop the compounds and
technologies under license. If terminated, we would lose the right to develop
the products, which could adversely affect our business. The license
agreements also generally require us to meet specified milestones or show
reasonable diligence in development of the technology. If disputes arise over
the definition of these requirements or whether we have satisfied the
requirements in a timely manner, or if any other obligations in the license
agreements are disputed by the other party, the other party could terminate
the agreement and we could lose our rights to develop the licensed technology.
21
We need to obtain collaborative arrangements for manufacturing and marketing
of our potential products, or we will have to develop the expertise, obtain
the additional capital and spend the resources to perform those functions.
We do not have the staff or facilities to manufacture or market any products
being developed in our programs. We need to enter into collaborative
arrangements in the future to develop, commercialize, manufacture and market
products emerging from our antioxidant program. We also might seek a company to
develop the manufacturing capability for the liver precursor cell therapy being
developed by us and intend to seek a company to work with on development of a
liver assist device. We also plan to seek companies to market and manufacture
OP2000.
A large number of small biotechnology companies are seeking collaborators,
some of whom compete in the same therapeutic areas as our programs, and
obtaining and maintaining new collaborative arrangements will be difficult. We
might not be successful in entering into third party arrangements on acceptable
terms, if at all. If we are unable to obtain or retain third-party
manufacturing or marketing on acceptable terms, we might be delayed in our
ability to commercialize products. Substantial additional funds and personnel
would be required if we needed to establish our own manufacturing or marketing
operations. We might not be able to obtain adequate funding or establish such
capabilities at all or in a cost-effective manner.
Even if we do succeed in obtaining a collaborator for any of our programs,
the product might not be commercialized profitably, if at all. The compensation
owed to our manufacturer and marketers will reduce our profit margins and might
delay or limit our ability to develop, deliver and sell products on a timely
and competitive basis. Furthermore, one of these companies could pursue
alternative technologies or develop alternative compounds either on its own or
in collaboration with others, targeted at the same diseases as those involved
in our programs.
A manufacturer must conform to FDA regulations for the production and
packaging of products. If any of our manufacturers can not meet our needs or
applicable regulatory standards with respect to the timing, quantity or quality
of products, our development programs would be delayed.
We are in discussions with third parties to conduct the cell processing to
produce the liver precursor cells being developed by Incara. To begin clinical
trials, we must contract with a supplier to isolate the liver precursor cells
in compliance with FDA regulations. We have not yet established the terms of
any supply arrangement, and we might not be able to enter into any arrangements
on satisfactory terms. We also must establish and maintain sources of livers or
liver tissues from which the precursor cells can be isolated. We have
historically relied on several suppliers of liver tissues for research, but
entering into the clinical trial stage of development will increase our needs.
For clinical trials and ultimately for commercialization, we plan to obtain,
from the traditional organ transplant donor programs, livers which are not
suitable for full liver transplant.
If we cannot retain or hire qualified personnel, our programs could be
delayed.
We have only 21 employees and are highly dependent on the principal members
of the management and scientific staff, including in particular Clayton I.
Duncan, our Chairman, President and Chief Executive Officer. We also are highly
dependent on the academic collaborators for each of our programs. The loss of
key employees or academic collaborators could delay progress in our programs or
result in termination of them in their entirety.
We believe that our future success will depend in large part upon our
ability to attract and retain highly skilled scientific and managerial
personnel. We face competition for the kinds of personnel from other companies,
research and academic institutions, government entities and other
organizations. We might not be successful in hiring or retaining the personnel
needed for success.
22
If we do not obtain and maintain government authorizations to manufacture and
market products, our business will be significantly harmed.
Our research and development activities and the manufacturing and marketing
of our products are subject to extensive regulation by governmental authorities
in the United States and other countries. Clinical trials and the manufacturing
and marketing of products are subject to the testing and approval processes of
the FDA and foreign regulatory authorities. The process of obtaining required
regulatory approvals for our products from the FDA and other regulatory
authorities takes many years and is expensive. Data obtained from preclinical
and clinical activities are susceptible to varying interpretations, and if
regulatory authorities do not agree with our analyses of data, our product
programs could be delayed or regulatory approval could be withheld. Additional
government regulations might be promulgated which could delay or prevent
regulatory approval of our products. Even if these approvals are obtained,
post-marketing, adverse events or other monitoring of the products could result
in suspension or limitation of the approvals.
Product liability claims, if asserted against us in the future, could exceed
our insurance coverage and use our cash resources.
The pharmaceutical and biotechnology business exposes us to the risk of
product liability claims alleging that use of our products caused an injury or
harm. These claims can arise at any point in the development, testing,
manufacture, marketing or sale of pharmaceutical products, and might be made
directly by patients involved in clinical trials of our products, by consumers
or healthcare providers or by organizations selling such products. Product
liability claims can be expensive to defend even if the product did not
actually cause the injury or harm.
Insurance covering product liability claims becomes increasingly expensive
as a product moves through the development pipeline to commercialization. We
have obtained limited product liability insurance coverage for the clinical
trials for OP2000. However, the available insurance coverage might not be
sufficient to cover us against all potential losses due to liability, if any,
or to the expenses associated with defending liability claims. A product
liability claim successfully asserted against us could exceed our coverage and
require us to use our own cash resources, which would then not be available for
our own products.
In addition, some of our licensing agreements with third parties require us
to maintain product liability insurance. If we can not maintain acceptable
amounts of coverage on commercially reasonable terms, the corresponding
agreements would be subject to termination.
The costs of compliance with environmental, safety and similar laws could
increase our cost of doing business or subject us to liability in the event of
noncompliance.
Our business is subject to regulation under state and federal laws regarding
occupational safety, laboratory practices, environmental protection and the
use, generation, manufacture, storage and disposal of hazardous substances. We
might be required to incur significant costs in the future to comply with
existing or future environmental and health and safety regulations. Our
research activities involve the use of hazardous materials, chemicals and
radioactive compounds. Although we believe that our procedures for handling
such materials comply with applicable state and federal regulations, we cannot
eliminate the risk of accidental contamination or injury from these materials.
In the event of an accident, we could be liable for any resulting damages.
Provisions of our charter documents and Delaware law could lead to
entrenchment of our management which could discourage or delay offers to
acquire Incara, which might reduce the market price of our common stock and
the voting rights of the holders of common stock.
Provisions of our charter documents and Delaware law make it more difficult
for our stockholders to change the directors of Incara or for a third party to
acquire Incara, and might discourage a third party from
23
offering to acquire Incara, even if a change in control or in management would
be beneficial to our stockholders. These provisions also could limit the price
that certain investors might be willing to pay in the future for shares of
common stock.
The Board of Directors of Incara has the authority to issue up to 3,000,000
shares of preferred stock in one or more series, and to determine the prices,
rights, preferences, privileges and restrictions, including voting rights, of
the shares within each series without any further vote or action by the
stockholders. The rights of the holders of Incara common stock will be subject
to, and may be adversely affected by, the rights of the holders of any
preferred stock that may be issued in the future. The issuance of preferred
stock with voting rights could make it more difficult for a third party to
acquire a majority of the outstanding voting stock.
Further, some provisions of Delaware law could delay or make more difficult
a merger, tender offer or proxy contest involving Incara. Incara is subject to
the antitakeover provisions of Section 203 of the Delaware General Corporation
Law. In general, the statute prohibits a publicly held Delaware corporation
from engaging in a business combination with an interested stockholder for a
period of three years after the date of the transaction in which the person
became an interested stockholder, unless the business combination is approved
in a prescribed manner. While such provisions are intended to enable the
Incara Board of Directors to maximize stockholder value, they might have the
effect of discouraging takeovers that could be in the best interest of some
stockholders. Such provisions could reduce the market value of Incara's common
stock in the future.
We remain contingently liable for certain IRL obligations.
Despite the sale of Incara Research Laboratories, or IRL, in December 1999
to a private pharmaceutical company, we remain contingently liable through May
2007 on debt and lease obligations assumed by the purchaser, including the IRL
facility lease in Cranbury, New Jersey. If the purchaser were to default, or
the lender or landlord otherwise collect from us, our financial condition
would be materially adversely affected. This contingent liability was
approximately $8,328,000 in September 2000 and should decline on an
approximately straight-line basis to zero in May 2007.
If we do not reach the market with our products before our competitors offer
products for the same use, or if we do not compete effectively in marketing
our products, the revenues from product sales, if any, will be reduced.
We face intense competition in all of our development programs. The markets
for therapeutic products that address inflammatory, liver and pulmonary
diseases are large and competition is expected to increase. Our most
significant competitors are fully integrated pharmaceutical companies and more
established biotechnology companies, which have substantially greater
financial, technical, sales and marketing, and human resources than us. These
companies might succeed in obtaining regulatory approval for competitive
products more rapidly than we can for our products. In addition, competitors
might develop technologies and products that are cheaper, safer or more
effective than those being developed by us or that would render our technology
obsolete.
If we fail to meet Nasdaq National Market listing requirements, our common
stock will be delisted and become illiquid.
Our common stock is currently listed on the Nasdaq National Market. Nasdaq
has requirements that a company must meet in order to remain listed on the
Nasdaq National Market. If we continue to experience losses from our
operations or we are unable to raise additional funds, we might not be able to
maintain the standards for continued quotation on the Nasdaq National Market,
including a minimum bid price requirement of $1.00.
If as a result of the application of these listing requirements, our common
stock were delisted from the Nasdaq National Market, our stock would become
harder to buy and sell. Further, our stock could be subject to what are known
as the "penny stock" rules. The penny stock rules place additional
requirements on broker-
24
dealers who sell or make a market in such securities. Consequently, if we were
removed from the Nasdaq National Market, the ability or willingness of broker-
dealers to sell or make a market in our common stock might decline. As a
result, your ability to resell your shares of our common stock could be
adversely affected.
Item 2. Properties.
Incara currently leases 9,444 square feet of office space in Research
Triangle Park, North Carolina, which is leased through April 2001. We are
negotiating a lease for other facilities and believe adequate facilities are
available in the area to meet our current and future needs.
Item 3. Legal Proceedings.
We are not a party to any material legal proceedings.
Item 4. Submission of Matters to a Vote of Security Holders.
No matters were submitted to a vote of security holders during the fourth
quarter ended September 30, 2000.
25
Executive Officers
The executive officers of Incara and their ages as of November 30, 2000 are
as follows:
Name Age Position
---- --- --------
Clayton I. Duncan.... 51 President, Chief Executive Officer and Chairman of
the Board of Directors
Richard W. Reichow... 50 Executive Vice President, Chief Financial Officer,
Treasurer and Secretary
David P. Ward, M.D... 54 Executive Vice President, Research and Development
John P. Richert...... 50 Vice President, Market Development
W. Bennett Love...... 45 Vice President, Corporate Planning/Communications
Clayton I. Duncan has been President, Chief Executive Officer and a director
of Incara since January 1995. From 1989 until December 1993, Mr. Duncan was
President and Chief Executive Officer of Sphinx Pharmaceuticals Corporation, a
biopharmaceutical company which was acquired by Eli Lilly and Company in
September 1994. From December 1993 until September 1994, he served as an
independent consultant to Sphinx with regard to the sale of Sphinx to Lilly.
From 1987 to 1989, Mr. Duncan was a General Partner of Intersouth Partners, a
venture capital firm. From 1979 to 1987, he was an executive with Carolina
Securities Corporation, a regional investment banking firm, serving as
Executive Vice President and a director from 1984 to 1987. Mr. Duncan was
founder and Chairman of the Board of CRX Medical, Inc., a medical products
company that conducted research and development in wound management, ophthalmic
disorders and interventional radiology. Mr. Duncan is also a director of Aeolus
Pharmaceuticals, Inc., CPEC LLC, and Renaissance Cell Technologies, Inc., all
of which are subsidiaries of Incara. Mr. Duncan received an M.B.A. from the
University of North Carolina at Chapel Hill. In addition, Mr. Duncan is a
director of The Forest at Duke, a continuing care retirement community, and
Chairman of the Board of Directors of the Carolina Ballet, a professional
ballet company.
Richard W. Reichow has been Executive Vice President since July 1998,
Secretary since October 1995, and Senior Vice President, Chief Financial
Officer and Treasurer since March 1995. Mr. Reichow was employed by Sphinx as
President and Chief Executive Officer from December 1993 to September 1994, as
Vice President, Finance & Administration from August 1991 to September 1994,
and as Chief Financial Officer and Treasurer from March 1990 to September 1994.
Between September 1994 and March 1995, he was an independent financial
consultant. Mr. Reichow was Vice President, Chief Financial Officer and
Treasurer of CRX Medical from 1987 to 1990. Mr. Reichow is a Certified Public
Accountant.
David P. Ward, M.D. has been Executive Vice President, Research and
Development of Incara since July 1998, and was Senior Vice President, Research
& Development from March 1995 to July 1998. Dr. Ward was Group Vice President,
Medical, Regulatory Affairs and Clinical Operations of Quintiles Transnational
Corporation, a contract research organization, from October 1994 to March 1995.
Dr. Ward was Vice President of Clinical Development and Regulatory Affairs of
Sphinx from January 1992 to September 1994. Prior to that time, Dr. Ward was
employed by SmithKline Beecham, a multinational pharmaceutical company, for
more than six years, serving as a Vice President in various clinical areas. Dr.
Ward received his M.D. degree from Case Western Reserve University Medical
School.
John P. Richert has been employed by Incara since 1995, and has been Vice
President, Market Development since December 1996. Mr. Richert served as
Director, Market Development with Sphinx from 1991 to 1994. Mr. Richert was
employed by Schering-Plough Corporation, a major pharmaceutical manufacturer,
from 1981 to 1990 where he held positions of increasing responsibility in
marketing. Mr. Richert received an M.B.A. in Pharmaceutical Marketing from
Fairleigh-Dickinson University.
W. Bennett Love has been employed by Incara since 1995, and has been Vice
President, Corporate Planning/Communications since June 1997. From 1990 to
1994, Mr. Love was employed as Sphinx as Director, Corporate Planning/
Communications. From 1983 through 1989, he was an investment banker with a
regional securities firm. Mr. Love received an M.B.A. from the University of
North Carolina at Chapel Hill.
26
PART II
Item 5. Market for Company's Common Equity and Related Stockholder Matters.
(a) Price Range of Common Stock
Our common stock trades on the Nasdaq National Market under the symbol
"INCR". The following sets forth the quarterly high and low sales prices as
reported by Nasdaq for the periods indicated. These prices are based on
quotations between dealers, which do not reflect retail mark-up, markdown or
commissions, and do not necessarily represent actual transactions.
High Low
--------- --------
Fiscal Year Ended September 30, 1999
October 1, 1998 through December 31, 1998............... $10 1/8 $3 3/8
January 1, 1999 through March 31, 1999.................. 15 1/2 5
April 1, 1999 through June 30, 1999..................... 8 1/4 4 1/16
July 1, 1999 through September 30, 1999................. 5 5/8 1/2
Fiscal Year Ended September 30, 2000
October 1, 1999 through December 31, 1999............... 1 13/16 1/2
January 1, 2000 through March 31, 2000.................. 11 1 17/32
April 1, 2000 through June 30, 2000..................... 6 1/8 1 1/2
July 1, 2000 through September 30, 2000................. 4 3/4 1 11/16
(b) Approximate Number of Equity Security Holders
As of October 31, 2000, the number of record holders of our common stock was
152 and we estimate that the number of beneficial owners was approximately
5,000.
(c) Dividends
We have never paid a cash dividend on our common stock and do not anticipate
paying cash dividends in the foreseeable future.
Item 6. Selected Financial Data.
You should read the following selected financial data in conjunction with
our consolidated financial statements and the notes to those statements and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" included elsewhere in this Form 10-K. We derived the consolidated
statements of operations data for the fiscal years ended September 30, 1996,
1997, 1998, 1999 and 2000 and the consolidated balance sheet data at September
30, 1996, 1997, 1998, 1999 and 2000 from our consolidated financial statements
which have been audited by PricewaterhouseCoopers LLP, independent accountants,
and, except for the consolidated statements of operations for the fiscal years
ended September 30, 1996 and 1997 and the consolidated balance sheet data at
September 30, 1996, 1997 and 1998, are included elsewhere in this Form 10-K.
Please be advised that historical results are not necessarily indicative of
the results to be expected in the future, particularly given our acquisition
and disposition history. Our historical cash expenditures prior to December 31,
1999 were significantly higher than our current cash spending rate. This lower
level of expenditures has resulted from the discontinuance of the IRL and
BEXTRA(R) programs (see "Item 1--Business--Discontinued Programs").
27
Statement of Operations Data:
(In thousands, except per share data)
Year Ended September 30,
-----------------------------------------------
2000 1999 1998 1997 1996
-------- -------- -------- -------- -------
Revenue:
Contract and license fee
revenue................... $ 100 $ 2,088 $ 6,121 $ 5,360 $ 5,348
-------- -------- -------- -------- -------
Costs and expenses:
Research and development... 7,645 18,996 16,799 19,972 5,276
Purchase of in-process
research and development.. 6,664 -- 5,343 411 350
General and
administrative............ 2,613 3,045 3,509 4,179 3,396
-------- -------- -------- -------- -------
Total costs and
expenses................ 16,922 22,041 25,651 24,562 9,022
-------- -------- -------- -------- -------
Loss from operations......... (16,822) (19,953) (19,530) (19,202) (3,674)
Gain on sale of division..... 9,751 -- -- -- --
Investment income, net....... 406 355 384 831 719
Income taxes................. -- -- -- -- (37)
Minority interest............ -- -- -- 568 (568)
-------- -------- -------- -------- -------
Net loss..................... $ (6,665) $(19,598) $(19,146) $(17,803) $(3,560)
======== ======== ======== ======== =======
Net loss per common share:
Basic and diluted.......... $ (1.06) $ (2.98) $ (2.69) $ (2.55) $ (0.59)
======== ======== ======== ======== =======
Weighted average common
shares outstanding:
Basic and diluted.......... 6,312 6,583 7,113 6,982 6,062
======== ======== ======== ======== =======
Balance Sheet Data:
(In thousands)
September 30,
-----------------------------------------------
2000 1999 1998 1997 1996
-------- -------- -------- -------- -------
Cash and cash equivalents and
marketable securities....... $ 6,555 $ 4,960 $ 23,562 $ 37,580 $37,391
Working capital ............. $ 4,662 $ 2,207 $ 14,607 $ 9,855 $28,870
Total assets................. $ 7,348 $ 8,044 $ 27,836 $ 42,623 $40,650
Long-term portion of capital
lease obligations and notes
payable..................... $ 43 $ 981 $ 1,593 $ 2,128 $ 896
Total liabilities............ $ 2,536 $ 4,253 $ 8,160 $ 29,167 $ 9,401
Total stockholders' equity... $ 4,812 $ 3,791 $ 19,676 $ 13,456 $30,680
Unaudited Pro Forma Consolidated Financial Information:
The consolidated financial statements of Incara are included elsewhere in
this Form 10-K. You should read the unaudited pro forma consolidated financial
information presented herein in conjunction with those financial statements and
related notes.
The unaudited pro forma consolidated financial information of Incara for the
year ended September 30, 2000 include adjustments to give effect in the
unaudited pro forma condensed consolidated statement of operations for the
disposition of IRL as if it had occurred on October 1, 1999.
The unaudited pro forma condensed consolidated statements of operations are
provided for informational purposes and are not necessarily indicative of the
results of operations that would have been achieved had the transactions been
in effect as of the beginning of the period presented and are not necessarily
indicative of future results of operations.
28
Pro Forma Consolidated Statement of Operations:
(In thousands, except per share data)
Fiscal Year Ended September 30, 2000
--------------------------------------
Pro Forma
Consolidated Adjustments-- Pro Forma
Actual IRL As Adjusted
------------ ------------- -----------
Revenue:
Contract and license fee revenue...... $ 100 $ 100 $ --
-------- ------- ---------
Costs and expenses:
Research and development.............. 7,645 1,339 6,306
Purchased in-process research and
development.......................... 6,664 -- 6,664
General and administrative............ 2,613 -- 2,613
-------- ------- ---------
Total costs and expenses............ 16,922 1,339 (15,583)
-------- ------- ---------
Loss from operations.................... (16,822) (1,239) (15,583)
Gain on sale of division................ 9,751 9,751 --
Interest income, net.................... 406 (37) 443
-------- ------- ---------
Net income (loss)....................... $ (6,665) $ 8,475 $ (15,140)
======== ======= =========
Net loss per common share:
Basic................................. $ (1.06) $ (2.40)
======== =========
Diluted............................... $ (1.06) $ (2.40)
======== =========
Weighted average common shares
outstanding............................ 6,312 6,312
======== =========
The pro forma adjustments reflect the elimination of revenue and expenses
related to IRL for the fiscal year ended September 30, 2000 as if the IRL sale
had occurred at the beginning of the fiscal year. The pro forma adjustments
also reflect the elimination of the gain recognized on the sale of IRL.
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Introduction
You should read the following discussion in conjunction with our
consolidated financial statements and the notes appearing elsewhere in this
Form 10-K. The following discussion contains forward-looking statements that
involve risks and uncertainties. Our actual results could differ materially
from those anticipated in the forward-looking statements as a result of various
factors, including those discussed in "Item 1--Business-- Risks Associated with
Our Business" and elsewhere in this Form 10-K.
Overview
We conduct discovery and development programs in three areas: (1)
inflammatory bowel disease, using an ultra-low molecular weight heparin known
as OP2000; (2) liver disorders, using liver precursor cell therapy; and (3)
small molecule antioxidants as a treatment for disorders resulting from
obstruction of blood flow, such as stroke and heart attack. Our current
programs reflect our business strategy of building a diversified portfolio of
innovative therapeutic products by advancing basic and clinical research
discoveries from leading academic research centers. Our strategy for bringing
promising treatments to the market includes entering into relationships with
companies who have the manufacturing, sales and marketing capabilities that we
do not have. We believe that collaborative agreements can provide funding and
expertise for the commercialization of our products, and allow us to maintain a
lower fixed cost structure.
On March 31, 2000, Incara acquired all of the minority interests of
Renaissance Cell Technologies, Inc. and Aeolus Pharmaceuticals, Inc. Prior to
this acquisition, Incara owned 78.0% of Renaissance and 65.8% of Aeolus. Incara
issued 1,220,041 shares of its common stock for the subsidiaries' minority
ownership. We
29
accounted for the acquisition using the purchase method of accounting with a
total purchase price of $6,664,000. We allocated the total purchase price to
purchased in-process research and development and immediately charged it to
operations because at the date of the acquisition the in-process research
purchased was in preclinical stages, feasibility had not been established and
we deemed it to have no alternative future use. We estimated at the acquisition
date that Renaissance and Aeolus would need to spend in excess of an additional
$50,000,000 to complete the research and development and that it would be at
least 2006 before the research and development is completed. We might share the
cost to complete research and development for these programs with collaborative
partners in the future. The acquisition of these minority interests should not
have a significant impact on future operating results because we previously
recognized all losses of Renaissance and Aeolus due to our majority interest in
the subsidiaries.
On December 29, 1999, we sold our anti-infective division, known as Incara
Research Laboratories, or IRL, to a private pharmaceutical company for
$11,000,000 in cash and the right to receive future payments totaling up to an
additional $4,000,000 if a compound originating from a collaboration with Merck
& Co., Inc. reaches preclinical and clinical trial milestones. We currently do
not expect to receive any additional payments from the purchaser. The
transaction involved the sale of assets associated with IRL, including rights
under the collaboration with Merck and the assumption of related liabilities by
the purchaser. We remain contingently liable through May 2007 on debt and lease
obligations of approximately $8,328,000 assumed by the purchaser, including the
IRL facility lease in Cranbury, New Jersey. We recognized a gain of $9,751,000
on the sale of IRL, which we recorded as other income. The effect of the IRL
transaction on Incara's historical financial statements is shown in "Pro Forma
Consolidated Financial Information."
In May 1998, Incara acquired all of the outstanding stock of Transcell
Technologies, Inc., a majority-owned subsidiary of Interneuron Pharmaceuticals,
Inc., through a merger with Transcell in exchange for Incara common stock,
stock options and stock warrants. We refer to the former Transcell operation as
Incara Research Laboratories, or IRL. We accounted for the purchase of
Interneuron's 77.9% interest in Transcell by Incara in a manner similar to a
"pooling-of-interests," because it represented a transfer of stock between
entities under common control. We accounted for the acquisition of the non-
Interneuron ownership interest by using the purchase method of accounting. We
have combined all of Transcell's past results of operations with our
consolidated results of operations. We issued stock in the Transcell merger in
three installments. We issued the first installment upon the closing of the
merger in May 1998. In lieu of the second installment payment due to
Interneuron in connection with the merger, Interneuron retained 281,703 shares
of Incara common stock as part of a corporate restructuring between Interneuron
and Incara. In August 1999, Incara issued 867,583 shares of Incara common stock
to the other former Transcell stockholders as payment for their second
installment of the merger. We issued the third and final installment of 856,861
shares of Incara common stock to the former Transcell stockholders, including
Interneuron, in February 2000. We calculated the number of shares issued using
a formula based on the market price of Incara common stock prior to the stock
issuance date. The issuance of these additional shares did not impact our
fiscal 2000 operating results because we included the value of these shares in
the determination of the purchase price of Transcell in fiscal 1998.
We had net losses of $6,665,000 and $19,598,000 for the fiscal years ended
September 30, 2000 and 1999, respectively. We had an accumulated deficit of
$83,907,000 at September 30, 2000. We have not yet generated any revenues from
product sales and do not expect to receive any product revenues in the
foreseeable future, if at all.
Results of Operations
Fiscal Year Ended September 30, 2000 Compared to Fiscal Year Ended September
30, 1999
Our net loss of $6,665,000 for fiscal 2000 was $12,933,000 less than the
$19,598,000 net loss for fiscal 1999. The net loss for fiscal 2000 resulted
from the net effect of recognizing a $9,751,000 gain on the sale of IRL, offset
by fiscal 2000 operating expenses and the write-off of $6,664,000 for purchased
in-process research and development in connection with the acquisition of
minority interests of Aeolus and Renaissance.
30
Contract and license fee revenue for fiscal 2000 was $100,000, as compared
to $2,088,000 for fiscal 1999. All of this revenue resulted from an IRL
collaboration with Merck. We will not receive any additional revenue from this
collaboration, because it was sold with the other IRL assets.
Our research and development, or R&D, expenses decreased $11,351,000, or
60%, to $7,645,000 in fiscal 2000 from $18,996,000 in fiscal 1999. The lower
expenses were primarily due to the result of discontinuing our bucindolol
development program in the fourth quarter of fiscal 1999 and to the sale of our
IRL operation in December 1999.
During the last quarter of fiscal 1999, we discontinued our bucindolol
development program and, therefore, we did not incur any bucindolol-related
expenses for fiscal 2000. During fiscal 1999, we incurred $6,469,000 of
bucindolol-related R&D expenses.
Because we sold IRL at the end of December 1999, we did not incur any
significant R&D expenses for IRL between January 1, 2000 and September 30,
2000. R&D expenses for IRL were $1,339,000 for fiscal 2000 and $8,245,000 for
fiscal 1999. We do not expect any additional expense for IRL in the future.
We incurred $1,712,000 of R&D expenses for OP2000 during fiscal 2000, versus
$228,000 during fiscal 1999. The higher expenses in fiscal 2000 were primarily
due to costs incurred in connection with our Phase 1 clinical trials that began
in October 1999 and were completed in April 2000, as well as preparation for a
Phase 2/3 clinical trial.
R&D expenses for our liver cell program increased $369,000, or 44%, to
$1,201,000 for fiscal 2000 from $832,000 for fiscal 1999. The higher expenses
in fiscal 2000 resulted primarily from more R&D staff time being devoted to the
program.
R&D expenses for our antioxidant program decreased $418,000, or 20%, to
$1,694,000 for fiscal 2000 from $2,112,000 for fiscal 1999. The decrease in
expenses from fiscal 1999 to fiscal 2000 was primarily due to the reduction of
outside contract services and sponsored research costs.
General and administrative, or G&A, expenses decreased $432,000, or 14%, to
$2,613,000 for fiscal 2000 from $3,045,000 for fiscal 1999. The higher G&A
expenses in fiscal 1999 were primarily for expenses related to the bucindolol
program, which we terminated in the last quarter of fiscal 1999, and the IRL
operation, which we sold in December 1999.
Fiscal Year Ended September 30, 1999 Compared To Fiscal Year Ended September
30, 1998
Our net loss of $19,598,000 for fiscal 1999 was $452,000, or 2%, greater
than the $19,146,000 net loss for fiscal 1998.
Contract and license fee revenue for fiscal 1999 was $2,088,000, as compared
to $6,121,000 for fiscal 1998. Contract and license fee revenue for fiscal 1999
primarily resulted from our collaboration with Merck. During fiscal 1999, we
received a $1,500,000 milestone payment from Merck for compounds that
demonstrated specific activity in laboratory tests using both resistant and
sensitive bacterial strains. Merck also funded $563,000 of research and
development costs at IRL during fiscal 1999.
Contract and license fee revenue for fiscal 1998 included (1) a $4,000,000
payment from Astra Pharmaceuticals, L.P. received pursuant to the termination
of a collaboration with Astra Merck Inc. for the development, manufacturing and
marketing of bucindolol in the United States, (2) $833,000 of U.S. bucindolol
development support from Astra Merck prior to the termination of the Astra
Merck collaboration, and (3) $1,138,000 of revenue recognized in conjunction
with the Merck collaboration.
Our research and development expenses increased $2,197,000, or 13%, to
$18,996,000 in fiscal 1999 from $16,799,000 in fiscal 1998.
31
Expenses for the development of bucindolol and general R&D expenses
increased $2,885,000, or 59%, to $7,807,000 for fiscal 1999 from $4,922,000 for
fiscal 1998. Our expenses increased after funding from the Astra Merck
collaboration ended in September 1998 and also increased as a result of the
costs of expanded European clinical trials for bucindolol during fiscal 1999.
Pursuant to the Astra Merck collaboration, during fiscal 1998 Astra Merck paid
for most expenses related to the development of the twice-daily formulation of
bucindolol for the United States, including liabilities assumed by Astra Merck
on our behalf of approximately $6,065,000. This additional amount did not flow
through our statements of operations, because it was offset against related
expenses. Because we terminated the Astra Merck collaboration in September
1998, we absorbed all of the U.S. development expenses for bucindolol in fiscal
1999. In addition, we expanded the European bucindolol clinical program with
BASF Pharma/Knoll AG during fiscal 1999, resulting in expense of approximately
$2,326,000 in fiscal 1999 versus approximately $1,309,000 in fiscal 1998. We
terminated the development of bucindolol in the last quarter of fiscal 1999 and
all estimated costs of termination were accrued as of September 30, 1999.
R&D expenses for IRL remained relatively constant, increasing by only
$44,000, or 1%, to $8,245,000 for fiscal 1999 from $8,201,000 for fiscal 1998.
During fiscal 1999 IRL incurred increased expenses for license fees paid to
Princeton University and patent preparation fees. These increased expenses were
offset by lower depreciation costs, because in fiscal 1998 we expensed $856,000
of Transcell property and equipment that did not meet our capitalization
criteria.
R&D expenses for Aeolus increased by $96,000, or 5%, to $2,112,000 for
fiscal 1999 from $2,016,000 for fiscal 1998, primarily due to an increase in
contract services for research and preclinical studies of its antioxidant small
molecule research program.
R&D expenses for Renaissance increased by $172,000, or 26%, to $832,000 for
fiscal 1999 from $660,000 for fiscal 1998, primarily due to increased fees for
patent preparation and a fee to the University of North Carolina for the
license of technology developed under the research agreement with UNC.
During fiscal 1998, we paid and expensed a $1,000,000 license fee for a
development compound licensed from Opocrin S.p.A.
In conjunction with the Transcell merger, we incurred a charge of $5,343,000
for the purchase of in-process research and development during fiscal 1998,
because feasibility of the in-process research and development acquired was not
yet established and we had no alternative future use for the technology. This
charge represents the market value of the shares of Incara stock issued to the
former minority interest owners of Transcell.
General and administrative expenses decreased by $464,000, or 13%, to
$3,045,000 for fiscal 1999 from $3,509,000 for fiscal 1998, primarily due to
the elimination of IRL administrative personnel and functions at IRL in
conjunction with the Transcell merger.
Liquidity and Capital Resources
At September 30, 2000, we had cash and cash equivalents and marketable
securities of $6,555,000, an increase of $1,595,000 from September 30, 1999.
Cash increased due to the receipt of $11,000,000 from the sale of IRL, offset
by operating costs for fiscal 2000.
In August 2000, we entered into a definitive agreement with Torneaux Fund
Ltd., an institutional investor, for an equity financing facility covering the
purchase of our common stock over 15 months. Under this facility, Incara
controls the amount and timing of stock sold to Torneaux, with the amount of
the investment being dependent, in part, on Incara's stock price. Assuming
Incara's stock price maintains a minimum threshold of $2.00, the cumulative
potential investment is anticipated to exceed $3,000,000 and is capped at
$18,900,000.
32
The agreement includes the issuance of warrants to purchase an amount of common
stock equal to 15% of the common stock shares purchased, and is subject to a
number of conditions.
While management believes its existing financial resources are adequate to
fund operations through fiscal 2001, the Company intends to rely on the
Torneaux financing facility or other financing arrangements to support a higher
level of R&D efforts during fiscal 2001. We expect to incur substantial
additional costs and losses over the next few years. Our cash requirements for
subsequent periods will depend on numerous factors, particularly the progress
of our research and development programs. We will require significant
additional funds to continue our clinical program evaluating the use of OP2000
and to complete preclinical activities, and to begin clinical trials for our
liver precursor cell and antioxidant programs. We might acquire other products,
technologies or businesses that complement our existing or planned products or
programs, although we currently have no understanding, commitment or agreement
with respect to any such acquisitions.
To execute our business plan, we intend to seek additional capital from one
or more potential sources, including the sale of common or preferred stock in
private or public equity offerings and from new collaborations related to one
or more of our product development programs. Adequate funds might not be
available at all or on terms acceptable or favorable to us. At times it is
difficult for biotechnology companies to raise funds in the equity markets. Any
additional equity financing, if available, would likely result in substantial
dilution to Incara's stockholders. If we are successful in obtaining
collaborations for any of our programs, we expect to relinquish rights to
technologies, product candidates or markets which we might otherwise develop
ourselves. If we are unable to enter into new collaborations or raise
additional capital to support our business plan, we might be required to scale
back, delay or discontinue one or more of our research and development
programs, such as our proposed clinical trials, or obtain funds on terms that
are not favorable to us, which could have a material adverse affect on our
business and the value of our common stock. Reduction or discontinuation of
research and development programs could result in additional charges, which
would be reflected in the period of the reduction or discontinuation.
In January 2000, our Board of Directors authorized the repurchase of up to
$2,000,000 of our common stock during the following two months through
purchases on the stock market. During fiscal 2000, we repurchased a total of
140,100 shares of our common stock at a total cost of $412,000.
Item 7A. Quantitative and Qualitative Disclosure of Market Risks.
Not applicable.
Item 8. Financial Statements and Supplementary Data.
See Index to Consolidated Financial Statements on page F-1.
Item 9. Changes In and Disagreements With Accountants on Accounting and
Financial Disclosure.
Not applicable.
33
PART III
Certain information required by Part III is omitted from this report because
the Registrant will file a definitive proxy statement for its 2001 Annual
Meeting of Stockholders (the "Proxy Statement") within 120 days after the end
of its fiscal year pursuant to Regulation 14A promulgated under the Securities
Exchange Act of 1934, as amended, and the information included therein is
incorporated herein by reference to the extent provided below.
Item 10. Directors and Executive Officers of the Registrant.
The information required by Item 10 of Form 10-K concerning the Registrant's
directors is incorporated by reference to the information under the heading
"Election of Directors" in the Proxy Statement. The information required by
Item 10 of Form 10-K concerning the Registrant's executive officers is set
forth under the heading "Executive Officers" located at the end of Part I of
this Form 10-K.
Compliance with Section 16(a) of the Securities Exchange Act of 1934.
To the Company's knowledge, there were no reports required under Section
16(a) of the Securities Exchange Act of 1934 that were not timely filed during
the fiscal year ended September 30, 2000.
Item 11. Executive Compensation.
The information required by Item 11 of Form 10-K is incorporated by
reference to the information under the heading "Proposal No. 1--Election of
Directors--Information Concerning the Board of Directors and Its Committees",
"Other Information--Compensation of Executive Officers", "--Compensation of
Directors", "--Report of the Compensation Committee on Executive Compensation",
"--Compensation Committee Interlocks and Insider Participation" and
"Performance Graph" in the Proxy Statement.
Item 12. Security Ownership of Certain Beneficial Owners and Management.
The information required by Item 12 of Form 10-K is incorporated by
reference to the information under the heading "Other Information--Principal
Stockholders" in the Proxy Statement.
Item 13. Certain Relationships and Related Transactions.
The information required by Item 13 of Form 10-K is incorporated by
reference to the information under the heading "Other Information--Certain
Transactions" in the Proxy Statement.
34
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K.
(a) The following Financial Statements, Financial Statement Schedules and
Exhibits are filed as part of this report or incorporated herein by reference:
(1) Financial Statements.
See Index to Consolidated Financial Statements on page F-1.
(2) Financial Statement Schedules.
All financial statement schedules for which provision is made in Regulation
S-X are omitted because they are not required under the related instructions,
are inapplicable, or the required information is given in the financial
statements, including the notes thereto.
(3) Exhibits.
Exhibit
No. Description
------- -----------
3.1 Certificate of Incorporation, as amended(a)
3.2 Bylaws(a)
3.3 Amendment to Bylaws dated September 23, 1999(m)
4.1 Form of Common Stock Certificate(m)
4.2 Form of Warrant to be issued to Torneaux Fund Ltd.(s)
10.1 Form of Investors' Rights Agreement(a)
10.4* License Agreement between Duke University and Aeolus Pharmaceuticals,
Inc., dated July 21, 1995(a)
10.7 Acquisition Agreement relating to the acquisition by Intercardia, Inc.
of 80% of CPEC, Inc. dated May 13, 1994, as amended(a)
10.8 Incara Pharmaceuticals Corporation 1994 Stock Option Plan, as
amended(n)
10.9 Office Lease between Highwoods/Forsyth Limited Partnership and
Intercardia, Inc., dated April 24, 1995(a)
10.10 Master Equipment Lease between Phoenix Leasing Incorporated and
Intercardia, Inc., dated June 12, 1995, and related Sublease and
Acknowledgment of Assignment to Aeolus Pharmaceuticals, Inc.(a)
10.11* Development and Marketing Collaboration and License Agreement between
Astra Merck Inc., Intercardia, Inc. and CPEC, Inc., dated December 4,
1995(a)
10.12 Incara Pharmaceuticals Corporation 1995 Employee Stock Purchase Plan,
as amended(o)
10.16 Tax Allocation Agreement between Interneuron Pharmaceuticals, Inc. and
Intercardia, Inc., dated December 4, 1995(a)
10.19 Lease Amendment Number One, dated March 6, 1996, to Office Lease
between Highwoods/Forsyth Limited Partnership and Intercardia, Inc.(b)
10.21* Agreement among Intercardia, Inc., CPEC, Inc. and Knoll AG dated
December 19, 1996(c)
10.22 Lease Amendment Number Two, dated March 14, 1997, to Office Lease
between Highwoods/Forsyth Limited Partnership and Intercardia, Inc.(d)
35
Exhibit
No. Description
------- -----------
10.23 Sponsored Research Agreement between The University of North Carolina
at Chapel Hill and Renaissance Cell Technologies, Inc. dated September
4, 1997(e)
10.24* Sponsored Research Agreement between National Jewish Medical and
Research Center and Aeolus Pharmaceuticals, Inc., dated September 11,
1997(e)
10.26 Employment Agreement between Clayton I. Duncan and Intercardia, Inc.,
dated December 15, 1997(e)
10.27 Assignment and Assumption and Royalty Agreement effective as of May 8,
1998 between Intercardia, Inc. and Interneuron Pharmaceuticals,
Inc.(f)
10.28* Research Collaboration and License Agreement dated effective as of
June 30, 1997, as amended, by and among Interneuron Pharmaceuticals,
Inc., Transcell Technologies, Inc. and Merck & Co., Inc., as assigned
to Intercardia, Inc. effective May 8, 1998(f)
10.29* License Agreement dated June 29, 1998 between Princeton University and
Intercardia, Inc.(f)
10.30 License Agreement dated April 15, 1998, effective as of June 30, 1997,
between Princeton University and Interneuron Pharmaceuticals, Inc., as
assigned to Intercardia, Inc. by Interneuron Pharmaceuticals, Inc.
effective May 8, 1998(f)
10.31 Lease Agreement dated September 19, 1996, as amended, between Cedar
Brook Corporate Center, L.P. and Transcell Technologies, Inc., as
assigned to Intercardia, Inc. effective May 8, 1998(f)
10.32 Amendment 1, dated as of July 1, 1998, to Sponsored Research Agreement
between National Jewish Medical and Research Center and Aeolus
Pharmaceuticals, Inc.(f)
10.33 Termination and Settlement Agreement dated September 29, 1998, between
Astra Pharmaceuticals, L.P., Intercardia, Inc. and CPEC, Inc.(g)
10.34* License, Development, Marketing and Clinical Trials Supply Agreement
between Opocrin S.p.A. and Intercardia, Inc., dated July 20, 1998(h)
10.35 Employment Agreement between Richard W. Reichow and Intercardia, Inc.,
dated November 16, 1998(h)
10.36 Employment Agreement between David P. Ward and Intercardia, Inc.,
dated November 16, 1998(h)
10.37 Employment Agreement between John P. Richert and Intercardia, Inc.,
dated November 16, 1998(h)
10.38 Employment Agreement between W. Bennett Love and Intercardia, Inc.,
dated November 16, 1998(h)
10.39* Development, Manufacturing, Marketing and License Agreement, effective
as of December 19, 1996, among Knoll AG, CPEC, Inc. and Intercardia,
Inc.(j)
10.40 Exchange Agreement dated July 15, 1999, between Intercardia, Inc. and
Interneuron Pharmaceuticals, Inc.(k)
10.41 Registration Rights Agreement dated July 15, 1999, between Interneuron
Pharmaceuticals, Inc. and Intercardia, Inc.(k)
10.42 Amended and Restated Limited Liability Company Agreement of CPEC LLC
dated July 15, 1999, among CPEC LLC, Intercardia, Inc. and Interneuron
Pharmaceuticals, Inc.(k)
10.43 Assignment, Assumption and License Agreement dated July 15, 1999,
between CPEC LLC and Intercardia, Inc.(k)
10.44 Incara Pharmaceuticals Corporation 1997 Equity Incentive Plan, Form of
Restricted Stock Award Agreement (7-month vesting) and Form of
Restricted Stock Award Agreement (3-year vesting)(l)
36
Exhibit
No. Description
------- -----------
10.45 Amendment No. 2, dated June 22, 1999, to Sponsored Research Agreement
between The University of North Carolina at Chapel Hill and
Renaissance Cell Technologies, Inc.(m)
10.46 Amendment 2, dated August 16, 1999, to Sponsored Research Agreement
between National Jewish Medical and Research Center and Aeolus
Pharmaceuticals, Inc.(m)
10.47 Form of Severance Agreement dated September 23, 1999 with Clayton I.
Duncan, Richard W. Reichow, David P. Ward, John P. Richert and W.
Bennett Love(m)
10.48* Asset Purchase Agreement dated December 17, 1999(m)
10.49* License Agreement dated August 23, 1999 between The University of
North Carolina at Chapel Hill and Renaissance Cell Technologies,
Inc.(o)
10.50* License Agreement, effective July 1996, between Albert Einstein
College of Medicine of Yeshiva University and Renaissance Cell
Technologies, Inc.(o)
10.51 Registration Rights Agreement dated August 17, 2000 between Incara
Pharmaceuticals Corporation and Torneaux Fund Ltd.(r)
10.52 Common Stock Purchase Agreement dated August 17, 2000 between Incara
Pharmaceuticals Corporation and Torneaux Fund Ltd.(q)
10.53 Employment Agreement between Clayton I. Duncan and Incara
Pharmaceuticals Corporation, dated December 11, 2000
10.54 Amendment No. 3, dated July 6, 2000, to Sponsored Research Agreement
between The University of North Carolina at Chapel Hill and
Renaissance Cell Technologies, Inc.
21.1 List of Subsidiaries(p)
23.1 Consent of PricewaterhouseCoopers LLP
27.1 Financial Data Schedule
- --------
* Confidential treatment granted.
(a) Incorporated by reference to the similarly numbered Exhibit to the
Company's Registration Statement on Form S-1 (File No. 333-08209).
(b) Incorporated by reference to the similarly numbered Exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended December 31,
1995.
(c) Incorporated by reference to the similarly numbered Exhibit to the
Company's Annual Report on Form 10-K for the fiscal year ended September
30, 1996.
(d) Incorporated by reference to the similarly numbered Exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended March 31,
1997.
(e) Incorporated by reference to the similarly numbered Exhibit to the
Company's Annual Report on Form 10-K for the fiscal year ended September
30, 1997.
(f) Incorporated by reference to the similarly numbered Exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended June 30,
1998.
(g) Incorporated by reference to the similarly numbered Exhibit to the
Company's Form 8-K Current Report filed on September 30, 1998.
(h) Incorporated by reference to the similarly numbered Exhibit to the
Company's Annual Report on Form 10-K for the fiscal year ended September
30, 1998.
(i) Incorporated by reference to the similarly numbered Exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended December 31,
1998.
(j) Incorporated by reference to the similarly numbered Exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended March 31,
1999.
37
(k) Incorporated by reference to the similarly numbered Exhibit to the
Company's Form 8-K Current Report filed on July 23, 1999.
(l) Incorporated by reference to the similarly numbered Exhibit to the
Company's Form 8-K Current Report filed on October 11, 1999.
(m) Incorporated by reference to the similarly numbered Exhibit to the
Company's Annual Report on Form 10-K for the fiscal year ended September
30, 1999.
(n) Incorporated by reference to the similarly numbered Exhibit to the
Company's Report on Form S-8 filed on March 30, 2000.
(o) Incorporated by reference to the similarly numbered Exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended March 31,
2000.
(p) Incorporated by reference to the similarly numbered Exhibit to the
Company's Registration Statement on Form S-1 (File No. 333-43050).
(q) Incorporated by reference to Appendix A of the Company's definitive proxy
statement filed on September 7, 2000.
(r) Incorporated by reference to Appendix B of the Company's definitive proxy
statement filed on September 7, 2000.
(s) Incorporated by reference to the similarly numbered Exhibit to the
Company's Registration Statement on Form S-1 (File No. 333-45822).
(b) Reports on Form 8-K.
(1) Filed July 21, 2000 to provide pro forma financial statements for
the sale of IRL.
38
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Accountants......................................... F-2
Consolidated Balance Sheets--As of September 30, 2000 and 1999............ F-3
Consolidated Statements of Operations--For the fiscal years ended
September 30, 2000, 1999 and 1998........................................ F-4
Consolidated Statements of Stockholders' Equity--For the fiscal years
ended September 30, 2000, 1999 and 1998.................................. F-5
Consolidated Statements of Cash Flows--For the fiscal years ended
September 30, 2000, 1999 and 1998........................................ F-6
Notes to Consolidated Financial Statements................................ F-7
F-1
REPORT OF INDEPENDENT ACCOUNTANTS
TO THE BOARD OF DIRECTORS AND STOCKHOLDERS OF
INCARA PHARMACEUTICALS CORPORATION
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations, stockholders' equity and cash flows
present fairly, in all material respects, the financial position of Incara
Pharmaceuticals Corporation and its subsidiaries (the "Company") at September
30, 2000 and 1999, and the results of their operations and their cash flows for
each of the three years in the period ended September 30, 2000, in conformity
with accounting principles generally accepted in the United States of America.
These financial statements are the responsibility of the Company's management;
our responsibility is to express an opinion on these financial statements based
on our audits. We conducted our audits of these statements in accordance with
auditing standards generally accepted in the United States of America, which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
PricewaterhouseCoopers LLP
Raleigh, North Carolina
November 15, 2000
F-2
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)
September 30,
------------------
2000 1999
-------- --------
ASSETS
Current assets:
Cash and cash equivalents................................ $ 1,877 $ 2,407
Marketable securities.................................... 4,678 2,553
Accounts receivable...................................... 197 282
Prepaids and other current assets........................ 403 237
-------- --------
Total current assets................................... 7,155 5,479
Property and equipment, net................................ 193 2,483
Other assets............................................... -- 82
-------- --------
$ 7,348 $ 8,044
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable......................................... $ 637 $ 654
Accrued expenses......................................... 1,807 1,933
Current portion of capital lease obligations............. 22 488
Current portion of notes payable......................... 27 197
-------- --------
Total current liabilities.............................. 2,493 3,272
Long-term portion of capital lease obligations............. 43 399
Long-term portion of notes payable......................... -- 582
Stockholders' equity:
Common stock, $.001 par value per share, 40,000,000
shares authorized, 7,365,849 and 5,226,969 shares issued
and outstanding at September 30, 2000 and 1999,
respectively............................................ 7 5
Additional paid-in capital............................... 88,951 81,772
Restricted stock......................................... (239) (744)
Accumulated deficit...................................... (83,907) (77,242)
-------- --------
Total stockholders' equity............................. 4,812 3,791
-------- --------
$ 7,348 $ 8,044
======== ========
The accompanying notes are an integral part of the consolidated financial
statements.
F-3
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Fiscal Year Ended
September 30,
----------------------------
2000 1999 1998
-------- -------- --------
Revenue:
Contract and license fee revenue............... $ 100 $ 2,088 $ 6,121
-------- -------- --------
Costs and expenses:
Research and development....................... 7,645 18,996 16,799
Purchase of in-process research and
development................................... 6,664 -- 5,343
General and administrative..................... 2,613 3,045 3,509
-------- -------- --------
Total costs and expense...................... 16,922 22,041 25,651
-------- -------- --------
Loss from operations............................. (16,822) (19,953) (19,530)
Gain on sale of division......................... 9,751 -- --
Investment income, net........................... 406 355 384
-------- -------- --------
Net loss......................................... $ (6,665) $(19,598) $(19,146)
======== ======== ========
Net loss per common share:
Basic.......................................... $ (1.06) $ (2.98) $ (2.69)
======== ======== ========
Diluted........................................ $ (1.06) $ (2.98) $ (2.69)
======== ======== ========
Weighted average common shares outstanding....... 6,312 6,583 7,113
======== ======== ========
The accompanying notes are an integral part of the consolidated financial
statements.
F-4
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Dollars in thousands)
Common Stock
----------------- Additional Total
Number Par Paid-in Restricted Deferred Accumulated Stockholders'
of Shares Value Capital Stock Compensation Deficit Equity
---------- ----- ---------- ---------- ------------ ----------- -------------
Balance at September 30,
1997................... 6,956,545 $ 7 $52,243 $ -- $ (296) $(38,498) $ 13,456
Exercise of common stock
options................ 15,576 -- 59 -- -- -- 59
Grants of common stock
options at below fair
value.................. -- -- 1,450 -- (1,450) -- --
Stock-based
compensation........... -- -- 464 -- -- -- 464
Amortization of deferred
compensation........... -- -- -- -- 660 -- 660
Proceeds from offerings
of Employee Stock
Purchase Plan.......... 13,592 -- 142 -- -- -- 142
Contribution to
Transcell capital by
Interneuron............ -- -- 18,698 -- -- -- 18,698
Common stock issued to
unrelated parties in
conjunction with
Transcell Merger....... 303,440 -- 5,343 -- -- -- 5,343
Net loss for the fiscal
year ended September
30, 1998............... -- -- -- -- -- (19,146) (19,146)
---------- ---- ------- ----- ------- -------- --------
Balance at September 30,
1998................... 7,289,153 7 78,399 -- (1,086) (57,644) 19,676
Exercise of common stock
options................ 21,851 -- 53 -- -- -- 53
Amortization of deferred
compensation........... -- -- -- -- 827 -- 827
Proceeds from offerings
of Employee Stock
Purchase Plan.......... 67,851 -- 134 -- -- -- 134
Contribution of payables
to capital by
Interneuron............ -- -- 2,421 -- -- -- 2,421
Cancellation of common
stock returned by
Interneuron............ (4,229,381) (4) 4 -- -- -- --
Common stock issued to
unrelated parties in
conjunction with
Transcell Merger....... 867,583 1 (1) -- -- -- --
Write-off of deferred
compensation related to
common stock options
cancelled.............. -- -- (259) -- 259 -- --
Restricted common stock
sold to employees and
consultants............ 1,209,912 1 755 (755) -- -- 1
Stock-based compensation
and amortization of
Restricted Stock....... -- -- 266 11 -- -- 277
Net loss for the fiscal
year ended September
30, 1999............... -- -- -- -- -- (19,598) (19,598)
---------- ---- ------- ----- ------- -------- --------
Balance at September 30,
1999................... 5,226,969 5 81,772 (744) -- (77,242) 3,791
Exercise of common stock
options................ 140,000 -- 50 -- -- -- 50
Proceeds from offerings
of Employee Stock
Purchase Plan.......... 208,744 -- 122 -- -- -- 122
Common stock issued in
conjunction with
Transcell Merger....... 856,861 1 (1) -- -- -- --
Common stock issued in
conjunction with Aeolus
and Renaissance
mergers................ 1,220,041 1 6,663 -- -- -- 6,664
Stock-based compensation
and amortization of
Restricted Stock....... -- -- 838 424 -- -- 1,262
Restricted Stock
forfeited.............. (146,666) -- (81) 81 -- -- --
Common stock
repurchased............ (140,100) -- (412) -- -- -- (412)
Net loss for the fiscal
year ended September
30, 2000............... -- -- -- -- -- (6,665) (6,665)
---------- ---- ------- ----- ------- -------- --------
Balance at September 30,
2000................... 7,365,849 $ 7 $88,951 $(239) $ -- $(83,907) $ 4,812
========== ==== ======= ===== ======= ======== ========
The accompanying notes are an integral part of the consolidated financial
statements.
F-5
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Fiscal Year Ended
September 30,
---------------------------
2000 1999 1998
------- -------- --------
Cash flows from operating activities:
Net loss........................................ $(6,665) $(19,598) $(19,146)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization................. 260 771 1,837
Noncash compensation.......................... 1,262 1,105 1,125
Purchase of in-process research and
development.................................. 6,664 -- 5,343
Gain on sale of division...................... (9,751) -- --
Loss on disposal of property and equipment.... 36 -- --
Interest expense on notes to Interneuron...... -- -- 918
Change in assets and liabilities:
Accounts receivable......................... 85 814 31
Prepaids and other assets................... (170) (117) 120
Accounts payable and accrued expenses....... (653) (1,356) (10,054)
Deferred revenue............................ -- -- (500)
------- -------- --------
Net cash used in operating activities..... (8,932) (18,381) (20,326)
------- -------- --------
Cash flows from investing activities:
Proceeds from sale of division.................. 11,000 -- --
Proceeds from sales and maturities of marketable
securities..................................... 6,468 11,406 20,400
Purchases of marketable securities.............. (8,593) (1,044) (13,920)
Purchases of property and equipment............. (114) (278) (1,110)
------- -------- --------
Net cash provided by investing
activities............................... 8,761 10,084 5,370
------- -------- --------
Cash flows from financing activities:
Net proceeds from issuance of stock and
warrants....................................... 172 187 201
Proceeds from capital leases.................... 38 -- --
Repurchase of common stock...................... (412) -- --
Proceeds from notes payable..................... 2 2 460
Principal payments on notes payable............. (58) (194) (117)
Principal payments on capital lease
obligations.................................... (101) (494) (345)
Advances from Interneuron, net.................. -- 556 7,219
------- -------- --------
Net cash provided by (used by) financing
activities............................... (359) 57 7,418
------- -------- --------
Net decrease in cash and cash
equivalents.............................. (530) (8,240) (7,538)
Cash and cash equivalents at beginning of period.. 2,407 10,647 18,185
------- -------- --------
Cash and cash equivalents at end of period........ $ 1,877 $ 2,407 $ 10,647
======= ======== ========
Supplemental disclosure of investing and financing
activities:
Cash payments of interest....................... $ 37 $ 251 $ 222
======= ======== ========
Contribution of payables to capital by
Interneuron.................................... $ -- $ 2,421 $ --
======= ======== ========
Property and equipment acquired through
financing arrangements......................... $ 38 $ -- $ 110
======= ======== ========
The accompanying notes are an integral part of the consolidated financial
statements.
F-6
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A. NATURE OF THE BUSINESS
The Company conducts discovery and development programs in three areas: (1)
inflammatory bowel disease, using an ultra-low molecular weight heparin; (2)
liver disorders, using a novel form of hepatic progenitor cell therapy; and (3)
novel small molecule catalytic antioxidants for disorders such as stroke and
heart attack.
The "Company" refers collectively to Incara Pharmaceuticals Corporation
("Incara") and its wholly owned subsidiaries, Aeolus Pharmaceuticals, Inc., a
Delaware corporation ("Aeolus"), and Renaissance Cell Technologies, Inc., a
Delaware corporation ("Renaissance"). At September 30, 2000, the Company also
owned a 35.0% interest in CPEC LLC, a Delaware limited liability company
("CPEC").
Until July 15, 1999, Incara was a majority-owned subsidiary of Interneuron
Pharmaceuticals, Inc. ("Interneuron"). On July 15, 1999, Incara restructured
its corporate relationship with Interneuron to reduce Interneuron's majority
ownership of Incara in exchange for an increased ownership by Interneuron of
CPEC (the "Restructuring"). Prior to the Restructuring, CPEC was owned 80.1% by
Incara and 19.9% by Interneuron. Subsequent to the Restructuring, CPEC became
owned 35.0% by Incara and 65.0% by Interneuron (see Note I).
Until July 1999, the Company's most advanced product was BEXTRA(R)
(bucindolol HCl), a beta-blocker that was being evaluated in a Phase 3 clinical
trial conducted by the National Institutes of Health and the U.S. Department of
Veterans Affairs for use in treating congestive heart failure patients. The
agencies terminated the study in July 1999, prior to its scheduled termination
date, because an interim data analysis indicated there was no significant
survival advantage of treatment with bucindolol for the patient population as a
whole. In August 1999, the Company agreed to end the collaboration (the "Knoll
Collaboration") with BASF Pharma/Knoll AG ("Knoll") for BEXTRA for countries
outside the United States and Japan (the "Knoll Territory"), and terminated the
European trial of BEXTRA. The Company does not expect to pursue the compound
further for this or any other indication.
In May 1998, Incara acquired all of the outstanding stock of Transcell
Technologies, Inc. ("Transcell"), a majority-owned subsidiary of Interneuron,
in a merger of Transcell with and into Incara and also acquired certain related
technology rights held by Interneuron in exchange for Incara common stock,
stock options and stock warrants (the "Transcell Merger"). The purchase of
Interneuron's 77.9% interest in Transcell by Incara was treated in a manner
similar to a "pooling-of-interests," because it represented a transfer of stock
between entities under common control, and the acquisition of the non-
Interneuron ownership interest was accounted for by using the "purchase" method
of accounting. All of Transcell's past results of operations have been combined
with the results of operations for the Company, and the Company's financial
statements for all prior periods presented have been restated to reflect the
Transcell Merger.
On December 29, 1999, the Company sold the former Transcell operation, which
is referred to as Incara Research Laboratories ("IRL"), to a private
pharmaceutical company for $11,000,000 and the right to receive up to an
additional $4,000,000 in the event a compound originating from the Research
Collaboration and Licensing Agreement (the "Merck Collaboration"), originally
entered into among Transcell, Interneuron and Merck & Co., Inc. ("Merck"),
reaches certain preclinical and clinical trial milestones. The Company
currently does not expect to receive any additional payments from the
purchaser. The transaction involved the sale of assets associated with IRL,
including rights under the Merck Collaboration and the assumption of certain
related liabilities by the purchaser. The Company remains contingently liable
through May 2007 on debt and lease obligations of approximately $8,328,000
assumed by the purchaser, including the IRL facility lease in Cranbury, New
Jersey.
F-7
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
On March 31, 2000, Incara purchased all of the minority interests of
Renaissance and Aeolus. Prior to the acquisitions, Incara owned 78.0% of
Renaissance and 65.8% of Aeolus. Incara issued 1,220,041 shares of its common
stock in exchange for the subsidiaries' minority ownership. The acquisitions
have been accounted for using the purchase method of accounting. The total
purchase price of $6,664,000 consisted of 1,220,041 shares of Incara's common
stock with a fair value of $5.46 per share, based on the price of the Company's
common stock at the date of acquisition. The total purchase price was allocated
to purchased in-process research and development and immediately charged to
operations because at the date of the acquisition the in-process research
purchased was in preclinical stages, feasibility had not been established and
it was deemed to have no alternative future use.
B. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation: The consolidated financial statements include the
accounts of Incara and its wholly owned subsidiaries. The Company uses the
equity method to account for its 35.0% ownership interest in CPEC. All
significant intercompany accounts and transactions have been eliminated.
Use of Estimates: The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents: The Company invests available cash in short-term
bank deposits, money market funds, commercial paper and U.S. Government
securities. Cash and cash equivalents include investments with maturities of
three months or less at the date of purchase. The carrying value of cash and
cash equivalents approximate their fair market value at September 30, 2000 and
1999 due to their short-term nature.
Marketable Securities: The Company considers its investment portfolio
available-for-sale. Debt and equity securities are reported at fair value, with
unrealized gains and losses excluded from earnings and reported as a separate
component of stockholders' equity, net of related income taxes. Premiums are
amortized and discounts accreted using the interest method over the remaining
terms of the related securities. Gains and losses on the sale of securities are
determined using the specific identification method. The amortized cost of
marketable securities approximates their market value, yielding no unrealized
holding gains or losses at September 30, 2000 and 1999. At September 30, 2000,
the Company owned $4,678,000 of bank certificates of deposit due within one
year. At September 30, 1999 the Company owned $2,553,000 of corporate notes due
within one year.
Accounts Receivable: The accounts receivable balances at September 30, 2000
and 1999 are primarily comprised of amounts due from Interneuron for a portion
of the amount payable by the Company to Knoll for bucindolol-related
liabilities.
Property and Equipment: Property and equipment are stated at cost.
Depreciation and amortization are provided using the straight-line method based
on estimated useful lives or, in the case of leasehold improvements and
equipment under capital leases, over the lesser of the estimated useful lives
or the lease terms. The estimated useful lives are two years for computers and
five years for equipment. No impairments of property and equipment were
required to be recognized during the fiscal years ended September 30, 2000 and
1999. Subsequent to the Transcell Merger in May 1998, the Company wrote off
$856,000 of property and equipment acquired from Transcell because certain
items did not meet the Company's minimum cost per item capitalization criteria.
The majority of the Company's property and equipment at September 30, 1999
related to the IRL operations, which was sold in December 1999.
F-8
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Expenses for repairs and maintenance are charged to operations as incurred.
Upon retirement or sale, the cost of the assets disposed of and the related
accumulated depreciation are removed from the accounts, and any resulting gain
or loss is credited or charged to operations.
Revenue Recognition: Revenue is recognized under collaboration or research
and development agreements when services are performed or when contractual
obligations are met. Cash received in advance of revenue recognition is
recorded as deferred revenue.
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements" ("SAB 101"), which provides guidance on the recognition,
presentation and disclosure of revenue in financial statements filed with the
SEC. SAB 101, as amended by SAB 101A and SAB101B, outlines the basic criteria
that must be met to recognize revenue and provides guidance for disclosures
related to revenue recognition policies. Adoption is required by the Company no
later than the quarter ending September 30, 2001. The Company does not expect
SAB 101 to have a significant impact on the Company's revenue recognition
policies.
Research and Development: Research and development costs are expensed in the
period incurred. Payments related to the acquisition of in-process research and
development are either capitalized or expensed based upon the stage of
development of the acquired compound or technology at the date of acquisition.
Income Taxes: Deferred tax assets and liabilities are determined based on
the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the
differences are expected to affect taxable income. Valuation allowances are
established when necessary to reduce net deferred tax assets to the amounts
expected to be realized.
Net Loss Per Common Share: Basic net loss per common share is computed using
the weighted average number of shares of common stock outstanding during the
period. Diluted net loss per common share is computed using the weighted
average number of shares of common and dilutive potential common shares
outstanding during the period. Potential common shares consist of stock
options, warrants and convertible preferred stock using the treasury stock
method and are excluded if their effect is antidilutive. At September 30, 2000
had such potential common shares not been antidilutive, their effect would be
to increase the shares used in computing diluted net loss per common share by
500,291 shares to 6,812,143 shares.
Accounting for Stock-Based Compensation: The Company accounts for stock-
based compensation based on the provisions of Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB No. 25"),
which states that no compensation expense is recorded for stock options or
other stock-based awards to employees that are granted with an exercise price
equal to or above the estimated fair value per share of the Company's common
stock on the grant date. The Company has adopted the disclosure requirements of
Statement of Financial Accounting Standards No. 123, "Accounting for Stock-
Based Compensation" ("SFAS 123"), which requires compensation expense to be
disclosed based on the fair value of the options granted at the date of the
grant.
Segment Reporting: The Company currently operates in only one segment.
Recent Accounting Pronouncements: In June 1998, the Financial Accounting
Standards Board ("FASB") issued Statement of Financial Accounting Standards
("SFAS") No. 133, "Accounting for Derivative Instruments and Hedging
Activities" ("SFAS 133"). SFAS 138 was issued in June 2000 and provides certain
amendments to SFAS 133 and must be implemented at the same time as SFAS 133.
SFAS 133 and SFAS 138 establish accounting and reporting standards for
derivative instruments, including certain derivative instruments embedded in
other contracts (collectively referred to as derivatives), and for hedging
activities. As issued, SFAS 133 is effective for all fiscal quarters of all
fiscal years beginning after June 15,
F-9
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
1999, with earlier application encouraged. In May 1999, the FASB delayed the
effective date of SFAS 133 for one year, to fiscal quarters of all fiscal years
beginning after June 15, 2000. The Company does not currently use, nor does it
intend in the future to use, derivative instruments and, therefore, does not
expect that the adoption of SAFS 133 and SFAS 138 will have any impact on its
financial position or results of operations.
C. PROPERTY AND EQUIPMENT
Property and equipment consisted of the following at September 30, 2000 and
1999 (in thousands):
2000 1999
----- -------
Office equipment............................................. $ 428 $ 735
Laboratory equipment......................................... 341 1,411
Leasehold improvements....................................... 58 1,774
----- -------
827 3,920
Less: accumulated depreciation and amortization.............. (634) (1,437)
----- -------
$ 193 $ 2,483
===== =======
The above amounts included equipment under capital lease obligations with a
cost of $268,000 and $930,000 at September 30, 2000 and 1999, respectively, and
a net book value of $57,000 and $394,000 at September 30, 2000 and 1999,
respectively. Depreciation expense was $260,000 and $771,000 for the fiscal
years ended September 30, 2000 and 1999, respectively.
D. ACCRUED EXPENSES
At September 30, 2000 and 1999, accrued expenses consisted of the following
(in thousands):
2000 1999
------ ------
Payroll-related liabilities................................... $ 446 $ 305
Bucindolol development costs.................................. 1,350 1,619
Other......................................................... 11 9
------ ------
$1,807 $1,933
====== ======
E. COMMITMENTS
The Company leases office and laboratory space under non-cancelable
operating leases. Rent expense under non-cancelable operating leases was
$423,000, $1,147,000 and $1,154,000 for the fiscal years ended September 30,
2000, 1999 and 1998, respectively. The Company also leases equipment under
capital leases.
At September 30, 2000, the Company's non-cancelable future minimum payments
under lease arrangements were as follows (in thousands):
Operating Capital
Leases Leases
--------- -------
2001....................................................... $ 116 $ 28
2002....................................................... -- 28
2003....................................................... -- 19
----- ----
Total minimum lease payments............................. $ 116 75
=====
Less: amount representing interest......................... (10)
----
Present value of future minimum lease payments............. $ 65
====
F-10
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The Company remains contingently liable through May 2007 on debt and lease
obligations of approximately $8,328,000 assumed by the purchaser of IRL,
including the IRL facility lease in Cranbury, New Jersey.
F. NOTES PAYABLE
Notes payable at September 30, 2000 and 1999 consisted of the following (in
thousands):
2000 1999
----- -----
Note payable to North Carolina Biotechnology Center, including
accrued interest at 8.75%, principal and interest due in
December 2000................................................ $ 27 $ 25
Note payable to minority stockholder of Renaissance, including
accrued interest at 5.79%.................................... -- 29
Note payable to a financial institution, including accrued
interest at 13.4%............................................ -- 297
Note payable to IRL facility landlord, including accrued
interest at 11.5%............................................ -- 428
----- -----
Notes payable, including current maturities................... 27 779
Less: current maturities...................................... (27) (197)
----- -----
Long-term notes payable....................................... $ -- $ 582
===== =====
G. STOCKHOLDERS' EQUITY
Preferred Stock: The Certificate of Incorporation of Incara authorizes the
issuance of up to 3,000,000 shares of Preferred Stock, at a par value of $.01
per share. The Board of Directors has the authority to issue Preferred Stock in
one or more series, to fix the designation and number of shares of each such
series, and to determine or change the designation, relative rights,
preferences, and limitations of any series of Preferred Stock, without any
further vote or action by the stockholders of the Company. No shares of
Preferred Stock were outstanding at September 30, 2000 and 1999.
Common Stock: In May 1998, Incara issued 494,823 shares of common stock as
the first installment of the Transcell Merger (see Note J). In lieu of the
second installment payment due to Interneuron, Interneuron retained 281,703
shares of Incara common stock as part of the Restructuring (see Note I). On
August 9, 1999, Incara issued 867,583 shares of Incara common stock, valued at
approximately $1.38 per share, to the other former Transcell stockholders as
payment for their second installment of the Transcell Merger in the principal
amount of $1,202,000. Incara issued the third and final installment of the
purchase price of 856,861 shares of Incara common stock, valued at
approximately $3.36 per share, to the former stockholders of Transcell on
February 8, 2000. The issuance of these additional shares did not impact the
Company's operating results, because the value of these shares was included in
the determination of the purchase price of Transcell in fiscal 1998.
In January and February 2000, Incara repurchased 104,100 shares of its
common stock at a cost of $331,000 through purchases on the stock market. In
July 2000, Incara purchased from each of Lola M. Reid, Ph.D. and James D.
Crapo, M.D., both of whom are consultants to Incara, 18,000 shares of Incara's
common stock at a per share price of $2.25, the closing price as listed on
Nasdaq on July 26, 2000. The shares repurchased had been issued to Drs. Reid
and Crapo in the acquisitions of Renaissance and Aeolus on March 31, 2000.
F-11
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Restricted Stock: As an integral component of a management and employee
retention program designed to motivate, retain and provide incentive to the
Company's management, employees and key consultants, the Company's Board of
Directors adopted the 1999 Equity Incentive Plan (the "1999 Plan") in September
1999. The 1999 Plan provides for the grant of restricted stock ("Restricted
Stock") awards which entitle employees and consultants to receive up to an
aggregate of 1,400,000 shares of common stock upon satisfaction of specified
vesting periods. During September 1999, an aggregate of 1,209,912 shares of
Restricted Stock were granted to employees and key consultants of the Company
(the "Participants") in consideration of services rendered by the Participants
to the Company, the cancellation of options for an equal number of shares of
common stock and payment of the par value of the shares. A total of 578,437
shares of Restricted Stock were unvested at September 30, 2000. These remaining
shares of Restricted Stock vest in equal quarterly installments through October
2001.
The Company has incurred and will continue to incur compensation expense
through the vesting period of the Restricted Stock. The value of the Restricted
Stock awards of 1,209,912 shares at the date of the grant totaled $755,000,
based on the trading price of the Company's common stock of $0.625 per share.
The value of the Restricted Stock is amortized on a straight-line basis over
the vesting period. The Company recognized $424,000 and $11,000 of expenses
related to these awards during fiscal 2000 and 1999, respectively.
Employee Stock Purchase Plan: In October 1995, Incara adopted the Employee
Stock Purchase Plan (the "ESPP"). In April 2000, the stockholders approved an
amendment to increase the common stock reserved for issuance under the ESPP to
400,000 shares. Offerings are for one-year periods beginning on October 1 of
each year (an "Offering") and are divided into two six-month Purchase Periods
(the "Purchase Periods"). Employees may contribute up to ten percent (10%) of
gross wages, with certain limitations, via payroll deduction, to the ESPP.
Common stock is purchased at the end of each Purchase Period with employee
contributions at the lower of 85% of the closing price of Incara's common stock
on the first day of an Offering or the last day of the related Purchase Period.
As of September 30, 2000, Incara had sold 319,072 shares of common stock
pursuant to the ESPP and 80,928 shares were reserved for future issuances.
Stock Option Plan: Under Incara's 1994 Stock Option Plan (the "1994 Plan"),
incentive stock options ("ISOs") or non-qualified stock options to purchase
2,500,000 shares of Incara's common stock may be granted to employees,
directors and consultants of the Company. The exercise price of the ISOs
granted under the 1994 Plan must not be less than the fair market value of the
common stock as determined on the date of the grant. The options may have a
term up to 10 years. Options typically vest over three to four years following
the date of the grant.
F-12
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Stock option activity under the 1994 Plan was as follows:
Weighted
Average
Exercise
Shares Price
---------- --------
Outstanding at September 30, 1997....................... 1,416,710 $ 9.89
Granted............................................... 1,901,886 $ 9.61
Exercised............................................. (15,629) $ 3.77
Cancelled............................................. (1,032,835) $19.18
----------
Outstanding at September 30, 1998....................... 2,270,132 $ 5.47
Granted............................................... 95,500 $ 5.66
Exercised............................................. (21,851) $ 2.45
Cancelled............................................. (1,359,220) $ 7.53
----------
Outstanding at September 30, 1999....................... 984,561 $ 2.70
Granted............................................... 781,540 $ 3.93
Exercised............................................. (140,000) $ 0.36
Cancelled............................................. (288,941) $ 5.57
----------
Outstanding at September 30, 2000....................... 1,337,160 $ 3.05
==========
In August 1998, Incara's Board of Directors approved a resolution whereby
current employees and consultants were granted the right to amend the terms of
stock options with an exercise price greater than $11.00 per share. The amended
options reduced the exercise price to $8.00 per share, which was the trading
value of Incara's stock on the date of the repricing, and extended the vesting
period of the stock options.
The details of stock options outstanding at September 30, 2000 were as
follows:
Options Outstanding Options Exercisable
---------------------------------- ----------------------
Number Weighted Number
Outstanding Weighted Average Exercisable Weighted
at Average Remaining at Average
Range of September 30, Exercise Contractual September 30, Exercise
Exercise Prices 2000 Price Life 2000 Price
- --------------- ------------- -------- ----------- ------------- --------
$0.04 17,029 $ 0.04 6.1 years -- --
$0.36 283,048 $ 0.36 4.4 years 283,048 $ 0.36
$0.60 - $0.81 90,500 $ 0.63 5.7 years 83,832 $ 0.63
$1.00 162,809 $ 1.00 4.9 years 162,809 $ 1.00
$1.75 - $2.00 141,855 $ 1.88 9.5 years 66,855 $ 1.75
$2.37 - $5.09 106,517 $ 3.38 9.4 years 17,571 $ 4.39
$5.12 458,000 $ 5.12 9.5 years 426,998 $ 5.12
$7.12 - $8.00 50,026 $ 7.62 7.7 years 42,497 $ 7.64
$11.03 - $20.50 27,376 $14.42 5.6 years 27,376 $14.42
--------- ---------
1,337,160 $ 3.05 7.4 years 1,110,986 $ 3.08
========= =========
Under the principles of APB No. 25, the Company does not recognize
compensation expense associated with the grant of stock options to employees
unless an option is granted with an exercise price at less than fair market
value. SFAS 123 requires the use of option valuation models to recognize as
expense stock option grants to consultants and to provide supplemental
information regarding options granted to employees after September 30, 1995.
F-13
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The Company's pro forma information utilizing the Black-Scholes option
valuation model for the fiscal years ended September 30, 2000, 1999 and 1998 is
as follows:
2000 1999 1998
------ ------- -------
Net loss (in thousands):
As reported........................................ $6,665 $19,598 $19,146
Pro forma.......................................... $6,965 $20,889 $22,353
Basic and diluted net loss per share:
As reported........................................ $ 1.06 $ 2.98 $ 2.69
Pro forma.......................................... $ 1.10 $ 3.17 $ 3.14
Pro forma information regarding net loss was determined as if the Company
had accounted for its employee stock options and shares sold under the ESPP
under the fair value method of SFAS 123. The fair value of each option grant is
estimated on the date of the grant using the Black-Scholes option valuation
model with the following weighted-average assumptions used for grants:
2000 1999 1998
----------- ----------- -----------
Dividend yield......................... 0% 0% 0%
Expected volatility.................... 133% 85% 70%
Risk-free interest rate................ 6.0% - 6.3% 4.8% - 5.3% 5.3% - 5.6%
Expected option life after shares are
vested................................ 2 years 3 years 2 years
For the fiscal years ended September 30, 2000, 1999 and 1998, all stock
options issued were either issued at fair market value or were replacement
stock options issued pursuant to the Transcell Merger. During fiscal 1998,
Transcell granted stock options to consultants with an exercise price below
fair market value on the date of the grant.
Warrants: In May 1998, Incara issued replacement stock warrants to purchase
17,783 shares of Incara common stock at an exercise price of $13.49 in
connection with the Transcell Merger. As of September 30, 2000, warrants to
purchase 66,816 shares were outstanding, 49,033 of which are exercisable at an
exercise price of $8.25 per share until February 2001, and 17,783 of which are
exercisable at an exercise price of $13.49 per share until May 2003.
H. INCOME TAXES
As of September 30, 2000 and 1999, the Company had federal net operating
loss carryforwards of $57,359,000 and $56,375,000, respectively, and state
operating loss carryforwards of $18,493,000 and $17,509,000, respectively. The
use of these federal net operating loss carryforwards might be subject to
limitation under the rules regarding a change in stock ownership as determined
by the Internal Revenue Code. The federal net operating losses will begin to
expire in 2010. The state net operating losses will begin to expire in 2001.
F-14
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Significant components of the Company's deferred tax assets at September 30,
2000 and 1999 consisted of the following (in thousands):
2000 1999
-------- --------
Net operating loss carryforwards......................... $ 20,448 $ 20,063
AMT credit carryforwards................................. 37 37
Research and development credit carryforwards............ 1,195 1,195
Accrued payroll related liabilities...................... 1,204 1,521
Charitable contribution carryforwards.................... 637 441
Other.................................................... 495 533
-------- --------
Total deferred tax assets.............................. 24,016 23,790
Valuation allowance for deferred assets.................. (24,016) (23,790)
-------- --------
Net deferred tax asset................................. $ -- $ --
======== ========
Due to the uncertainty surrounding the realization of the favorable tax
attributes in future tax returns, all of the deferred tax assets have been
fully offset by a valuation allowance. The change in the valuation allowance is
primarily a result of the net operating loss carryforwards.
Taxes computed at the statutory federal income tax rate of 34% are
reconciled to the provision for income taxes as follows (dollars in thousands):
2000 1999 1998
------- ------- -------
Effective tax rate............................... 0% 0% 0%
======= ======= =======
United States Federal statutory rate............. $(2,266) $(6,663) $(6,510)
State taxes (net of federal benefit)............. 1 (273) 853
Change in valuation reserves..................... 226 4,909 4,394
Gain on sale of subsidiary....................... -- 2,371 --
Pipeline research and development................ 2,273 -- 1,464
Other............................................ (234) (344) (201)
------- ------- -------
Provision for income taxes..................... $ -- $ -- $ --
======= ======= =======
I. BUCINDOLOL TRANSACTIONS
In September 1994, Incara acquired 80.0% of the outstanding stock of CPEC.
CPEC held the exclusive, worldwide license from Bristol-Myers Squibb Company to
develop bucindolol for congestive heart failure and left ventricular
dysfunction.
In December 1995, the Company entered into a collaboration with Astra Merck
Inc. ("Astra Merck") for the development of bucindolol in the United States
(the "Astra Merck Collaboration"). During the fiscal year ended September 30,
1998, the Company recognized contract revenue of $834,000 from payments made by
Astra Merck to the Company, exclusive of a termination fee of $4,000,000
received in September 1998 discussed below. During the fiscal year ended
September 30, 1998, Astra Merck funded $6,065,000 of the Company's research and
development expenses. These additional amounts did not flow through the
Company's statements of operations, because they were offset against related
expenses. Pursuant to the terms of the Astra Merck Collaboration, the Company
paid Astra Merck $10,000,000 in December 1997, which had been accrued as a
liability at September 30, 1997. In July 1998, Astra Merck's business was
restructured to combine it with Astra AB's wholly-owned subsidiary, Astra USA
Inc., in a new limited partnership in which Astra AB had
F-15
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
management control as the general partner. The new company, Astra
Pharmaceuticals, had an expanded product line that included a beta-blocker
(metoprolol succinate). Because metoprolol and bucindolol were both beta-
blockers being investigated for heart failure, Astra Pharmaceuticals and the
Company agreed in September 1998 to terminate the Astra Merck Collaboration.
Pursuant to the Termination and Settlement Agreement, Astra Pharmaceuticals
returned to the Company all rights, material and information relating to
bucindolol and paid it a termination fee in the amount of $4,000,000. This
payment was immediately recognized as contract and license fee revenue because
the Company had no ongoing obligations.
In December 1996, the Company entered into the Knoll Collaboration with
Knoll to develop bucindolol for the Knoll Territory. Knoll and the Company had
agreed to share the development costs of bucindolol for the Knoll Territory. In
general, Knoll was to pay approximately 60% of certain development and
marketing costs and the Company was to pay approximately 40% of such costs,
subject to certain maximum dollar limitations. The Company recognized contract
and license fee revenue from the Knoll Collaboration of $26,000 and $149,000
for the fiscal years ended September 30, 1999 and 1998, respectively.
On July 15, 1999, Incara restructured its corporate relationship with
Interneuron to reduce Interneuron's majority ownership of Incara in exchange
for an increased ownership by Interneuron of CPEC. Prior to the Restructuring,
CPEC was owned 80.1% by Incara and 19.9% by Interneuron. As a preliminary step
in the Restructuring, Incara acquired Interneuron's 19.9% interest in CPEC.
Incara redeemed 4,229,381 of the 4,511,084 shares of Incara Common stock owned
by Interneuron, in exchange for a 65.0% ownership of CPEC and cancellation of
liabilities owed to Interneuron by Incara and CPEC which totalled $2,421,000.
This cancellation was treated as a contribution to capital by Interneuron to
Incara. The Company's net investment in CPEC of $332,000 at September 30, 2000
is included in Prepaids and other current assets in the accompanying
consolidated balance sheet. The Company's share of CPEC's net operating
expenses since the date of the Restructuring are included in research and
development expenses in the accompanying consolidated statements of operations.
Before the Restructuring, Incara had funded approximately 80.1% of the net
worldwide expenses related to bucindolol and Interneuron funded approximately
19.9%, in proportion to their respective ownership interests in CPEC. After the
Restructuring, Incara and Interneuron are responsible for funding 35.0% and
65.0%, respectively, of CPEC's expenses related to the development of
bucindolol in the United States and Japan (the "CPEC Territory"). As part of
the Restructuring, Incara received an exclusive license of CPEC's rights in the
Knoll Territory and is responsible for all bucindolol expenses in the Knoll
Territory.
On July 29, 1999, the double-blind, placebo-controlled, Phase 3 study of
bucindolol known as BEST (Beta-blocker Evaluation of Survival Trial) was
terminated earlier than scheduled, based on an interim analysis by the Data and
Safety Monitoring Board that treatment with bucindolol did not demonstrate a
statistically significant improvement in survival in the patient population as
a whole. Based on the information, the Company does not expect to pursue the
compound further for this or any other indication. All estimated BEST
termination costs were accrued as of September 30, 1999.
On August 3, 1999, Knoll terminated the Knoll Collaboration. Knoll and
Incara also terminated the Phase 3 clinical study of bucindolol being conducted
in Europe, which was known as BEAT (Bucindolol Evaluation after Acute
myocardial infarction Trial). All estimated BEAT termination costs were accrued
as of September 30, 1999.
F-16
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
J. ACQUISITIONS AND DISPOSITION
Renaissance Cell Technologies, Inc. and Aeolus Pharmaceuticals, Inc.
On March 31, 2000, Incara purchased all of the minority interests of
Renaissance and Aeolus. Prior to the acquisitions, Incara owned 78.0% of
Renaissance and 65.8% of Aeolus. Incara issued 1,220,041 shares of its common
stock in exchange for the subsidiaries' minority ownership. The acquisitions
have been accounted for using the purchase method of accounting. The total
purchase price of $6,664,000 consisted of 1,220,041 shares of Incara's common
stock with a fair value of $5.46 per share, based on the price of the Company's
common stock at the date of acquisition. The total purchase price was allocated
to purchased in-process research and development and immediately charged to
operations because at the date of the acquisition the in-process research
purchased was in preclinical stages, feasibility had not been established and
it was deemed to have no alternative future use.
Additionally, Renaissance and Aeolus had no workforce or other tangible
fixed assets. Renaissance and Aeolus had incurred approximately $10,000,000 in
research and development costs prior to the acquisition of the minority
interests by Incara. Incara expects that it will take until at least 2006 to
complete development of all aspects of the research and that Renaissance and
Aeolus will need to spend in excess of an additional $50,000,000 to do so.
Transcell Technologies, Inc.
In May 1998, Incara acquired all of the outstanding stock of Transcell in a
merger of Transcell with and into Incara, and also acquired related technology
rights held by Interneuron in exchange for Incara common stock with an
aggregate market value of $14,200,000. In addition, Incara issued replacement
stock options and warrants to purchase 241,705 shares and 17,783 shares,
respectively, of Incara common stock to Transcell employees, consultants and
warrant holders, with a total estimated value of $1,507,000. Prior to the
Transcell Merger, Incara and Transcell were both majority-owned subsidiaries of
Interneuron. Under the terms of the Agreement and Plan of Merger between
Incara, Transcell and Interneuron dated March 2, 1998, Transcell stockholders
received Incara common stock in three installments. The first installment of
320,151 shares was issued upon closing the transaction on May 8, 1998 (the
"Closing"). In exchange for certain license and technology rights held by
Interneuron, and for Interneuron's continuing guarantee of certain of
Transcell's lease obligations, Incara issued to Interneuron 174,672 shares of
Incara common stock at Closing with a value of $3,000,000 at the date of
issuance and will pay Interneuron a royalty on net sales of certain products
that may result from the Merck Collaboration. In lieu of the second installment
payment due to Interneuron, Interneuron retained 281,703 shares of Incara
common stock as part of the Restructuring. On August 9, 1999, Incara issued
867,583 shares of Incara common stock, valued at approximately $1.38 per share,
to the other former Transcell stockholders as payment for their second
installment of the Transcell Merger in the principal amount of $1,202,000. On
February 8, 2000, Incara issued 856,861 shares of Incara common stock, valued
at approximately $3.36 per share, to Interneuron and the other former Transcell
stockholders as payment for the third and final installment. The acquisition of
Interneuron's 77.9% ownership interest in Transcell by Incara was treated in a
manner similar to a "pooling-of-interests", because it represented a transfer
of stock between entities under common control. The acquisition of the non-
Interneuron ownership interest was accounted for using the "purchase" method of
accounting. The Company incurred a charge to operations of $5,343,000 in fiscal
1998 for the purchase of the non-Interneuron interest in Transcell, because
feasibility of the in-process research and development was not yet established
and the technology had no alternative future use at the date of the
acquisition. All of Transcell's prior results of operations were combined with
the results of operations of the Company, because Transcell's minority interest
owners had no responsibility to fund their share of the losses of Transcell.
F-17
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
On December 29, 1999, the Company sold the former Transcell operation, known
as IRL, to a private pharmaceutical company for $11,000,000 in cash and the
right to receive up to an additional $4,000,000 if a compound originating from
the Merck Collaboration reaches preclinical and clinical trial milestones. The
Company currently does not expect to receive any additional payments from the
purchaser. The transaction involved the sale of assets associated with IRL,
including rights under the Merck Collaboration and the assumption of related
liabilities by the purchaser. The Company recognized a gain of $9,751,000 on
the sale of IRL. The Company remains contingently liable through May 2007 on
debt and lease obligations of approximately $8,328,000 assumed by the
purchaser, including the IRL facility lease in Cranbury, New Jersey.
K. AGREEMENTS
UNC License
Renaissance has a sponsored research agreement (the "UNC Agreement") with
the University of North Carolina at Chapel Hill ("UNC") which covers research
at UNC by scientists in the area of hepatic stem cells and which grants
Renaissance a first option to obtain an exclusive license to inventions
resulting from the agreement with UNC. Renaissance has agreed to reimburse UNC
for certain costs incurred in connection with the research, of which $338,000
remained to be paid as of September 30, 2000. In August 1999, Renaissance
obtained an exclusive worldwide license (the "UNC License") from UNC to make,
use and sell products using proprietary information and technology developed
under the UNC Agreement. Renaissance paid license fees of $75,000 to UNC and
will also pay milestones on certain development events and royalties on net
sales. Renaissance is also obligated to pay patent filing, prosecution,
maintenance and defense costs. Unless terminated earlier, the UNC License
continues until the last underlying patent expires.
Opocrin License
In July 1998, Incara licensed a development compound ("OP2000") from Opocrin
S.p.A., of Modena, Italy ("Opocrin"). Incara is investigating the use of OP2000
as a drug for the treatment of inflammatory bowl disease. The license is
worldwide except for Japan and Korea. During fiscal 1998, Incara made a
$1,000,000 license fee payment to Opocrin, which was expensed by the Company
because the compound was in the early clinical stage of development. Incara is
responsible for conducting clinical trials for OP2000 and is required to make
additional milestone payments to Opocrin upon initiation of Phase 3 clinical
trials, upon filing for regulatory approval, upon obtaining regulatory approval
and upon achieving specified annual sales.
Merck Collaboration
In July 1997, Transcell and Interneuron entered into the Merck Collaboration
to discover and commercialize certain novel antibacterial agents. The agreement
provided for Merck to make initial payments totaling $2,500,000 which included
a non-refundable commitment fee of $1,500,000 and a non-refundable option
payment of $1,000,000 plus research support during the first two years of the
agreement. Based upon estimated relative value of such licenses and rights, the
commitment fee and option payment was shared two-thirds by the Company and one-
third by Interneuron. The Company's share of revenue in conjunction with this
agreement was $100,000, $2,063,000 and $1,138,000 for the fiscal years ended
September 30, 2000, 1999 and 1998, respectively, including a $1,500,000
milestone payment received from Merck in August 1999. In conjunction with the
sale of IRL, the Company has transferred its rights and obligations under the
Merck Collaboration and its licenses with Princeton University to the
purchaser.
F-18
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Duke Licenses
Aeolus has obtained exclusive worldwide licenses (the "Duke Licenses") from
Duke University ("Duke") to develop, make, have made, use and sell products
using certain technology in the field of free radical and antioxidant research,
developed by certain scientists at Duke. Future discoveries in the field of
antioxidant research from these scientists' laboratories at Duke are also
covered by the Duke Licenses. The Duke Licenses require Aeolus to use its best
efforts to pursue development of products using the licensed technology and
compounds. These efforts are to include the manufacture or production of
products for testing, development and sale. Aeolus is also obligated to use its
best efforts to have the licensed technology cleared for marketing in the
United States by the U.S. Food and Drug Administration and in other countries
in which Aeolus intends to sell products using the licensed technology. Aeolus
will pay royalties to Duke on net product sales during the term of the Duke
Licenses, and milestone payments upon certain regulatory approvals and annual
sales levels. In addition, Aeolus is obligated under the Duke Licenses to pay
all or a portion of patent prosecution, maintenance and defense costs. Unless
earlier terminated, the Duke Licenses continue until the expiration of the last
to expire issued patent on the licensed technology.
National Jewish Medical and Research Center Agreement
Aeolus has a sponsored research agreement with National Jewish Medical and
Research Center ("NJC") which grants Aeolus an option to negotiate a royalty-
bearing exclusive license for certain technology, patents and inventions
resulting from research by certain individuals at NJC within the field of
antioxidant, nitrosylating and related areas. Aeolus has agreed to support
certain of NJC's costs incurred in performance of the research, of which
$75,000 remained to be paid as of September 30, 2000.
L. EQUITY FINANCING
In August 2000, Incara entered into a definitive agreement with Torneaux
Fund Ltd. ("Torneaux"), an institutional investor, for an equity financing
facility covering the purchase of Incara's common stock over 15 months. Under
this facility, Incara will control the amount and timing of stock sold to
Torneaux, with the amount of the investment being dependent, in part, on
Incara's stock price. Assuming Incara's stock price maintains a minimum
threshold, the cumulative potential investment is anticipated to exceed
$3,000,000 and is capped at $18,900,000. The agreement includes the issuance of
warrants to purchase an amount of common stock equal to 15% of the common stock
shares purchased and is subject to a number of conditions. Incara's
stockholders approved this financing transaction in October 2000.
F-19
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Incara Pharmaceuticals Corporation
/s/ Clayton I. Duncan
By: _________________________________
President and Chief Executive
Officer
Date: December 15, 2000
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following person on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Capacity Date
--------- -------- ----
/s/ Clayton I. Duncan Chairman of the Board of December 15, 2000
______________________________________ Directors, President and
Clayton I. Duncan Chief Executive Officer
(Principal Executive
Officer)
/s/ Richard W. Reichow Executive Vice President, December 15, 2000
______________________________________ Chief Financial Officer
Richard W. Reichow and Treasurer (Principal
Financial and Accounting
Officer)
/s/ Stephen M. Prescott Director December 15, 2000
______________________________________
Stephen M. Prescott
/s/ Edgar H. Schollmaier Director December 15, 2000
______________________________________
Edgar H. Schollmaier
/s/ David B. Sharrock Director December 15, 2000
______________________________________
David B. Sharrock